

来那度胺药物报告

lenalidomide Drug Report

打印报告


摘要信息

药物英文名	lenalidomide
药物中文名	来那度胺
药物别名	CC-5013; CDC-501, Revlimid
原研单位	Celgene Corporation
全球最高状态	2005年批准上市
中国是否上市	是

药物概述

来那度胺由新基（Celgene）公司研发，首先于2005年12月27日获美国食品药品监督管理局（FDA）批准上市，然后于2007年6月14日获欧洲药物管理局（EMA）批准上市，之后于2010年6月25日获日本医药品医疗器械综合机构（PMDA）批准上市。由新基公司在上述各地上市销售，商品名为Revlimid。来那度胺是沙利度胺（thalidomide）类似物，具有免疫调节，抗血管生成和抗肿瘤特性。在多发骨髓瘤细胞中，来那度胺和地塞米松（dexamethasone）协同作用，能够抑制细胞增殖，导致肿瘤细胞凋亡。该药与地塞米松联合使用，可用于治疗多发性骨髓瘤（MM）；也可用于治疗已接受过至少一种疗法，因有5q染色体缺失、存在或不存在其他细胞遗传学异常的低风险或中度-1风险的骨髓增生异常综合征（MSD）所致的输血依赖型贫血，以及用于治疗已接受过包含一次硼替佐米疗法的两次治疗后的复发和进展性套细胞淋巴瘤（MCL）。Revlimid为口服胶囊，每粒含2.5 mg、5 mg、10 mg、15 mg、20 mg或25 mg来那度胺。推荐剂量为对于多发性骨髓瘤（MM），每次25 mg，与40 mg地塞米松联合使用，每日1次；对于骨髓增生异常综合征（MSD），每次10 mg，每日1次；对于套细胞淋巴瘤（MCL），每次25 mg，每日1次。

API信息

结构式	
	化学名称：(3RS)-3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione CAS登记号：191732-72-6 分子式：C <sub>13</sub> H <sub>13</sub> N <sub>3</sub> O <sub>3</sub> 分子量：259.2637
及其对映异构体	

药理作用

ATC分类

L04AX04 抗肿瘤药和免疫机能调节药 > 免疫抑制剂 > 免疫抑制剂 > 其它免疫抑制剂

作用靶点

Prostaglandin-endoperoxide synthase 2 (PTGS2)

美国上市情况(1条)

申请号	商标名	活性成分	剂型/给药途径	批准时间	申请机构
021880	REVLIMID	LENALIDOMIDE	CAPSULE;ORAL	2005-12-27	CELGENE

欧盟上市情况(1条)

编号	药品名称	活性成分	剂型	上市许可持有人	获批时间
EMA/H/C/000717	Revlimid	lenalidomide		Celgene Europe Ltd	2007-06-14

日本上市情况(1条)

商标名	活性成份	申请类型	申请公司	批准日期
レブラミドカプセル2.5mg / レブラミドカプセル5mg	レナリドミド水和物		セルジーン株式会社	2015/12

主要上市公司及国家(5条)

国家名称	上市公司	商标名	活性成分	适应症	状态
Cz.	Celgene	Revlimid	Lenalidomide	多发性骨髓瘤	
Fr.	Celgene	Revlimid	Lenalidomide	多发性骨髓瘤	
Port.	Celgene	Revlimid	Lenalidomide	多发性骨髓瘤	
UK	Celgene	Revlimid	Lenalidomide	多发性骨髓瘤	
USA	Celgene	Revlimid	Lenalidomide	多发性骨髓瘤	

中国上市情况(4条)

药品名称	批准文号	药品规格	生产厂商	国产厂家数量	是否医保
来那度胺胶囊	H20130069	5mg	Celgene International Sarl	瑞士进口	
来那度胺胶囊	H20130070	10mg	Celgene International Sarl	瑞士进口	

药品名称	批准文号	药品规格	生产厂商	国产厂家数量	是否医保
来那度胺胶囊	H20130071	15mg	Celgene International Sarl	瑞士进口	
来那度胺胶囊	H20130072	25mg	Celgene International Sarl	瑞士进口	

中国注册申报情况(107条)

隐藏

受理号码	药品名称	申请类型	注册分类	承办日期	企业名称	办理状态	状态开始日期	审批结论
JXHL0800198	来那度胺胶囊	进口		2008-06-13	新基欧洲有限公司	制证完毕 - 已发批件	2009-11-19	批准临床
JXHL0800197	来那度胺胶囊	进口		2008-06-13	新基欧洲有限公司	制证完毕 - 已发批件	2009-11-19	批准临床
JXHL0800196	来那度胺胶囊	进口		2008-06-13	新基欧洲有限公司	制证完毕 - 已发批件	2009-11-19	批准临床
JXHL0800195	来那度胺胶囊	进口		2008-06-23	新基欧洲有限公司	制证完毕 - 已发批件	2009-11-19	批准临床
JXHL0900015	来那度胺胶囊	进口		2009-01-15	新基欧洲有限公司	制证完毕 - 已发批件	2009-11-19	批准临床
JXHL0900014	来那度胺胶囊	进口		2009-01-15	新基欧洲有限公司	制证完毕 - 已发批件	2009-11-19	批准临床
JXHL0900013	来那度胺胶囊	进口		2009-01-15	新基欧洲有限公司	制证完毕 - 已发批件	2009-11-19	批准临床
JXHL0900012	来那度胺胶囊	进口		2009-02-13	新基欧洲有限公司	制证完毕 - 已发批件	2009-11-19	批准临床
JXHL0900069	来那度胺胶囊	进口		2009-03-05	新基欧洲有限公司	制证完毕 - 已发批件	2009-11-19	批准临床
JXHL0900065	来那度胺胶囊	进口		2009-03-05	新基欧洲有限公司	制证完毕 - 已发批件	2009-11-19	批准临床
JXHL0900066	来那度胺胶囊	进口		2009-03-05	新基欧洲有限公司	制证完毕 - 已发批件	2009-11-19	批准临床
JXHL0900067	来那度胺胶囊	进口		2009-03-05	新基欧洲有限公司	制证完毕 - 已发批件	2009-11-19	批准临床
JXHL0900068	来那度胺胶囊	进口		2009-03-05	新基欧洲有限公司	制证完毕 - 已发批件	2009-11-19	批准临床
JXHL0900064	来那度胺胶囊	进口		2009-04-02	新基欧洲有限公司	制证完毕 - 已发批件	2009-11-19	批准临床
CXHL0900323	来那度胺胶囊	新药	3.1	2009-12-23	北京福瑞康正医药技术研究所	制证完毕 - 已发批件	2012-02-14	批准临床
CXHL0900324	来那度胺胶囊	新药	3.1	2009-12-23	北京福瑞康正医药技术研究所	制证完毕 - 已发批件	2012-02-14	批准临床

受理号码	药品名称	申请类型	注册分类	承办日期	企业名称	办理状态	状态开始日期	审批结论
CXHL0900325	来那度胺胶囊	新药	3.1	2009-12-23	北京福瑞康正医药技术研究所	制证完毕 - 已发批件	2012-02-14	批准临床
CXHL0900322	来那度胺	新药	3.1	2009-12-23	北京福瑞康正医药技术研究所	制证完毕 - 已发批件	2012-02-14	批准临床
CXHL0900517	来那度胺胶囊	新药	3.1	2010-03-25	南京卡文迪许生物工程技术有限公司	制证完毕 - 已发批件	2012-03-23	批准临床
CXHL0900519	来那度胺胶囊	新药	3.1	2010-03-25	南京卡文迪许生物工程技术有限公司	制证完毕 - 已发批件	2012-03-23	批准临床
CXHL0900518	来那度胺胶囊	新药	3.1	2010-03-25	南京卡文迪许生物工程技术有限公司	制证完毕 - 已发批件	2012-03-23	批准临床
CXHL0900516	来那度胺	新药	3.1	2010-03-25	南京卡文迪许生物工程技术有限公司	制证完毕 - 已发批件	2012-03-23	批准临床
JXHL1000177	来那度胺胶囊	进口		2010-06-04	新基欧洲有限公司	制证完毕 - 已发批件	2011-02-18	批准临床
JXHL1000178	来那度胺胶囊	进口		2010-06-04	新基欧洲有限公司	制证完毕 - 已发批件	2011-02-18	批准临床
JXHL1000176	来那度胺胶囊	进口		2010-06-04	新基欧洲有限公司	制证完毕 - 已发批件	2011-02-18	批准临床
JXHL1000175	来那度胺胶囊	进口		2010-06-07	新基欧洲有限公司	制证完毕 - 已发批件	2011-02-18	批准临床
CXHL1100113	来那度胺	新药	3.1	2011-03-17	南京华威医药科技开发有限公司	制证完毕 - 已发批件	2015-07-01	不批准
CXHL1100114	来那度胺胶囊	新药	3.1	2011-03-17	南京华威医药科技开发有限公司	制证完毕 - 已发批件	2015-07-01	不批准
CXHL1100115	来那度胺胶囊	新药	3.1	2011-03-17	南京华威医药科技开发有限公司	制证完毕 - 已发批件	2015-07-01	不批准
CXHL1100116	来那度胺胶囊	新药	3.1	2011-03-17	南京华威医药科技开发有限公司	制证完毕 - 已发批件	2015-07-01	不批准

受理号码	药品名称	申请类型	注册分类	承办日期	企业名称	办理状态	状态开始日期	审批结论
JXHS1100121	来那度胺胶囊	进口		2011-12-28	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2013-01-30	批准进口
JXHS1100123	来那度胺胶囊	进口		2011-12-28	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2013-01-30	批准进口
JXHS1100122	来那度胺胶囊	进口		2011-12-28	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2013-01-30	批准进口
JXHS1100120	来那度胺胶囊	进口		2011-12-28	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2013-01-30	批准进口
CXHL1100455	来那度胺胶囊	新药	3.1	2011-12-30	宁波立华制药有限公司	制证完毕 - 已发批件	2015-06-17	不批准
CXHL1100456	来那度胺胶囊	新药	3.1	2011-12-30	宁波立华制药有限公司	制证完毕 - 已发批件	2015-06-17	不批准
CXHL1100457	来那度胺胶囊	新药	3.1	2011-12-30	宁波立华制药有限公司	制证完毕 - 已发批件	2015-06-17	不批准
CXHL1100454	来那度胺	新药	3.1	2011-12-30	宁波立华制药有限公司	制证完毕 - 已发批件	2015-06-17	不批准
CXHL1200440	来那度胺胶囊	新药	3.1	2012-08-17	合肥信风科技开发有限公司	制证完毕 - 已发批件	2015-06-17	不批准
CXHL1200441	来那度胺胶囊	新药	3.1	2012-08-17	合肥信风科技开发有限公司	制证完毕 - 已发批件	2015-06-17	不批准
CXHL1200442	来那度胺胶囊	新药	3.1	2012-08-17	合肥信风科技开发有限公司	制证完毕 - 已发批件	2015-06-17	不批准
CXHL1200439	来那度胺	新药	3.1	2012-08-17	合肥信风科技开发有限公司	制证完毕 - 已发批件	2015-06-17	不批准
JXHL1300250	来那度胺胶囊	进口		2013-07-11	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2014-07-28	批准临床
JXHL1300251	来那度胺胶囊	进口		2013-07-11	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2014-07-28	批准临床

受理号码	药品名称	申请类型	注册分类	承办日期	企业名称	办理状态	状态开始日期	审批结论
JXHL1300252	来那度胺胶囊	进口		2013-07-11	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2014-07-28	批准临床
JXHL1300253	来那度胺胶囊	进口		2013-07-11	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2014-07-28	批准临床
JXHL1300249	来那度胺胶囊	进口		2013-07-16	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2014-07-28	批准临床
CXHS1300142	来那度胺	新药	3.1	2013-07-30	连云港宏创药业有限公司	制证完毕 - 已发批件	2015-12-10	不批准
CYHS1300803	来那度胺胶囊	仿制	6	2013-09-12	江苏豪森药业股份有限公司	制证完毕 - 已发批件	2015-12-15	批准临床
CYHS1300804	来那度胺胶囊	仿制	6	2013-09-12	江苏豪森药业股份有限公司	制证完毕 - 已发批件	2015-12-15	批准临床
CYHS1300805	来那度胺胶囊	仿制	6	2013-09-12	江苏豪森药业股份有限公司	制证完毕 - 已发批件	2015-12-15	批准临床
CYHS1300802	来那度胺胶囊	仿制	6	2013-09-12	江苏豪森药业股份有限公司	制证完毕 - 已发批件	2015-12-15	批准临床
CXHS1300267	来那度胺	新药	3.1	2013-12-02	连云港润众制药有限公司	制证完毕 - 已发批件	2016-01-21	批准临床
CYHS1301529	来那度胺胶囊	仿制	6	2014-02-14	正大天晴药业集团股份有限公司	制证完毕 - 已发批件	2016-01-21	批准临床
CYHS1301528	来那度胺胶囊	仿制	6	2014-02-14	正大天晴药业集团股份有限公司	制证完毕 - 已发批件	2016-01-21	批准临床
CYHS1301530	来那度胺胶囊	仿制	6	2014-02-14	正大天晴药业集团股份有限公司	制证完毕 - 已发批件	2016-01-21	批准临床
JYHB1400696	来那度胺胶囊	补充申请		2014-06-10	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2014-12-12	
JYHB1400697	来那度胺胶囊	补充申请		2014-06-10	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2014-12-12	

受理号码	药品名称	申请类型	注册分类	承办日期	企业名称	办理状态	状态开始日期	审批结论
JYHB1400698	来那度胺胶囊	补充申请		2014-06-10	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2014-12-12	
JYHB1400695	来那度胺胶囊	补充申请		2014-06-10	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2014-12-12	
JXHL1400216	来那度胺胶囊	进口		2014-06-27	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2015-08-10	批准临床
JXHL1400217	来那度胺胶囊	进口		2014-06-27	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2015-08-10	批准临床
JXHL1400215	来那度胺胶囊	进口		2014-06-27	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2015-08-10	批准临床
JXHL1400214	来那度胺胶囊	进口		2014-07-01	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2015-08-10	批准临床
CXHS1400204	来那度胺	新药	3.1	2014-08-28	新乡双鹭药业有限公司	在审评审批中	2014-08-26	
CXHL1401314	来那度胺	新药	3.1	2014-12-19	四川美大康华康药业有限公司	制证完毕 - 已发批件	2016-02-29	批准临床
CYHS1401241	来那度胺胶囊	仿制	6	2014-12-22	四川美大康华康药业有限公司	制证完毕 - 已发批件	2016-03-10	批准临床
CYHS1401242	来那度胺胶囊	仿制	6	2014-12-22	四川美大康华康药业有限公司	制证完毕 - 已发批件	2016-03-10	批准临床
CYHS1401240	来那度胺胶囊	仿制	6	2014-12-22	四川美大康华康药业有限公司	制证完毕 - 已发批件	2016-03-10	批准临床
JXHL1400420	来那度胺胶囊	进口		2014-12-29	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2016-01-21	批准临床
JXHL1400421	来那度胺胶囊	进口		2014-12-29	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2016-01-21	批准临床


受理号码	药品名称	申请类型	注册分类	承办日期	企业名称	办理状态	状态开始日期	审批结论
JXHL1400422	来那度胺胶囊	进口		2014-12-29	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2016-01-21	批准临床
JXHL1400423	来那度胺胶囊	进口		2014-12-29	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2016-01-21	批准临床
JXHL1400419	来那度胺胶囊	进口		2014-12-29	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2016-01-21	批准临床
JXHL1400418	来那度胺胶囊	进口		2015-01-04	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2016-01-21	批准临床
CXHS1400267	来那度胺胶囊	新药	3.1	2015-01-19	北京双鹭药业股份有限公司	在审评审批中	2015-01-14	
CXHS1400268	来那度胺胶囊	新药	3.1	2015-01-19	北京双鹭药业股份有限公司	在审评审批中	2015-01-14	
CXHS1400266	来那度胺胶囊	新药	3.1	2015-01-19	北京双鹭药业股份有限公司	在审评审批中	2015-01-14	
CXHL1401822	来那度胺	新药	3.1	2015-02-10	齐鲁安替（临邑）制药有限公司	制证完毕 - 已发批件	2016-02-29	批准临床
JXHL1500038	来那度胺胶囊	进口		2015-02-13	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2016-02-29	批准临床
JXHL1500039	来那度胺胶囊	进口		2015-02-13	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2016-02-29	批准临床
JXHL1500040	来那度胺胶囊	进口		2015-02-13	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2016-02-29	批准临床
JXHL1500037	来那度胺胶囊	进口		2015-02-13	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2016-02-29	批准临床
CXHL1401879	来那度胺	新药	3.1	2015-04-17	山东孔府制药有限公司	制证完毕 - 已发批件	2016-04-21	批准临床
CYHS1401670	来那度胺胶囊	仿制	6	2015-05-05	齐鲁制药有限公司	制证完毕 - 已发批件	2016-02-29	批准临床




受理号码	药品名称	申请类型	注册分类	承办日期	企业名称	办理状态	状态开始日期	审批结论
CYHS1401667	来那度胺胶囊	仿制	6	2015-05-05	齐鲁制药有限公司	制证完毕 - 已发批件	2016-02-29	批准临床
CYHS1401669	来那度胺胶囊	仿制	6	2015-05-05	齐鲁制药有限公司	制证完毕 - 已发批件	2016-02-29	批准临床
CYHS1401668	来那度胺胶囊	仿制	6	2015-05-05	齐鲁制药有限公司	制证完毕 - 已发批件	2016-02-29	批准临床
CYHS1401724	来那度胺胶囊	仿制	6	2015-06-01	山东孔府制药有限公司	制证完毕 - 已发批件	2016-04-21	批准临床
CYHS1401725	来那度胺胶囊	仿制	6	2015-06-01	山东孔府制药有限公司	制证完毕 - 已发批件	2016-04-21	批准临床
CYHS1401723	来那度胺胶囊	仿制	6	2015-06-01	山东孔府制药有限公司	制证完毕 - 已发批件	2016-04-21	批准临床
JYHB1500922	来那度胺胶囊	补充申请		2015-07-23	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2016-05-06	
JYHB1500923	来那度胺胶囊	补充申请		2015-07-23	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2016-05-06	
JYHB1500924	来那度胺胶囊	补充申请		2015-07-23	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2016-05-06	
JYHB1500921	来那度胺胶囊	补充申请		2015-07-23	新基医药信息咨询（上海）有限公司	制证完毕 - 已发批件	2016-05-06	
JXHS1600025	来那度胺胶囊	进口		2016-03-15	新基医药信息咨询（上海）有限公司	在审评审批中	2016-03-14	
JXHS1600026	来那度胺胶囊	进口		2016-03-15	新基医药信息咨询（上海）有限公司	在审评审批中	2016-03-14	
JXHS1600027	来那度胺胶囊	进口		2016-03-15	新基医药信息咨询（上海）有限公司	在审评审批中	2016-03-14	
JXHS1600024	来那度胺胶囊	进口		2016-03-15	新基医药信息咨询（上海）有限公司	在审评审批中	2016-03-14	

受理号码	药品名称	申请类型	注册分类	承办日期	企业名称	办理状态	状态开始日期	审批结论
JYHB1601214	来那度胺胶囊	补充申请		2016-09-12	新基医药信息咨询(上海)有限公司	在审评审批中	2016-09-08	
JYHB1601215	来那度胺胶囊	补充申请		2016-09-12	新基医药信息咨询(上海)有限公司	在审评审批中	2016-09-08	
JYHB1601216	来那度胺胶囊	补充申请		2016-09-12	新基医药信息咨询(上海)有限公司	在审评审批中	2016-09-08	
JYHB1601213	来那度胺胶囊	补充申请		2016-09-12	新基医药信息咨询(上海)有限公司	在审评审批中	2016-09-08	
CYHS1790002	来那度胺胶囊	仿制	6	2017-01-11	正大天晴药业集团股份有限公司	在审评审批中	2014-02-13	
CYHS1600170	来那度胺	仿制	3	2017-02-20	连云港润众制药有限公司	在审评审批中	2017-02-17	
CYHS1790016	来那度胺胶囊	仿制	6	2017-03-03	正大天晴药业集团股份有限公司	在审评审批中	2014-02-13	
CYHS1790015	来那度胺胶囊	仿制	6	2017-03-03	正大天晴药业集团股份有限公司	在审评审批中	2014-02-13	


申请类型



剂型



承办日期



药品说明书(20条)

隐藏

药品名称	来源	更新时间	操作
来那度胺胶囊	CelgeneInternationalSarl		<a href="#">查看全文</a>
レブラミドカプセル2.5mg,レブラミドカプセル5mg	製造販売:セルジーン/		<a href="#">查看</a>
REVLIMID	CELGENE	2010-08-10	
REVLIMID	CELGENE	2009-02-24	
REVLIMID	CELGENE	2010-10-19	

药品名称	来源	更新时间	操作
REVLIMID	CELGENE	2011-12-23	
REVLIMID	CELGENE	2013-02-12	
REVLIMID	CELGENE	2014-09-19	
REVLIMID	CELGENE	2015-02-24	
REVLIMID	CELGENE	2005-12-28	
REVLIMID	CELGENE	2006-07-03	
REVLIMID	CELGENE	2009-02-24	
REVLIMID	CELGENE	2009-02-24	
REVLIMID	CELGENE	2012-03-12	
REVLIMID	CELGENE	2012-05-10	
REVLIMID	CELGENE	2013-02-12	
REVLIMID	CELGENE	2013-06-05	
REVLIMID	CELGENE	2013-11-04	
REVLIMID	CELGENE	2014-09-19	
REVLIMID	CELGENE	2017-02-22	

全球临床试验情况(821条)					隐藏
注册题目	招募状态	试验分期	国家	登记时间	
<a href="#">Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma</a>	Recruiting		Portugal	2016-02-22	
<a href="#">R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma</a>	Suspended	Phase 1/Phase 2	United States	2016-02-22	
<a href="#">A study to decide what is the right dose of durvalumab to take in combination with lenalidomide with or without dexamethasone to treat a cancer of the bone marrow that is newly diagnosed.</a>	Ongoing	phase 1/phase 2	France;United States;Canada;Finland;Spain;Denmark;Netherlands;Germany;Italy	2016-02-18	
<a href="#">A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma</a>	Recruiting	Phase 1	United States;Canada;Denmark;Finland;France;Germany;Italy;Netherlands;Spain;Canada;Denmark;Finland;F	2016-02-16	
<a href="#">Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma</a>	Recruiting	Phase 3	United States	2016-01-15	
<a href="#">Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma</a>	Recruiting	Phase 1	United States	2016-01-12	

注册题目	招募状态	试验分期	国家	登记时间
A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma	Recruiting	Phase 2	United States	2015-12-17
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma	Recruiting	Phase 2	United States	2015-12-15
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma	Recruiting	Phase 1/Phase 2	United States;France;United Kingdom;France;United Kingdom;United States	2015-12-14
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma	Not yet recruiting	Phase 1/Phase 2	United States	2015-12-09
Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma	Recruiting	Phase 2	United States	2015-11-30
Efficacy and safety of lenalidomide and dexamethasone as consolidation therapy and lenalidomide as maintenance therapy after autologous stem cell transplantation for newly diagnosed multiple myeloma	Open public recruiting	Phase 2	Japan	2015-11-24
Efficacy and safety of dose-escalating lenalidomide and dexamethasone (Rd) for unfit patients with relapsed or refractory multiple myeloma	Open public recruiting	Phase 2	Japan	2015-11-24
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone (EPd) in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide	Recruiting	Phase 2	United States	2015-11-20
A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple Myeloma and the Treatment Patterns Following Progressive Disease	Recruiting		Greece	2015-11-17
Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma	Recruiting	Phase 2	Belgium;France;Belgium;France	2015-11-16
A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)	Recruiting	Phase 1/Phase 2	United States	2015-11-03
A Phase Ib study of lenalidomide in combination with imatinib for adult patients with chronic myeloid leukaemia in second molecular remission		Phase 1	Australia	2015-11-02

注册题目	招募状态	试验分期	国家	登记时间
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype	Not yet recruiting	Phase 1/Phase 2	United States;United States	2015-10-26
Study of Lenalidomide and Dexamethasone with or without Pembrolizumab in Newly Diagnosed and Treatment-Naïve Multiple Myeloma.	Ongoing	phase 3	United States;Spain;Russian Federation;Israel;United Kingdom;Italy;France;Canada;Brazil;Australia;So	2015-10-15
GEM-CLARIDEX: Ld vs BiRd	Recruiting	Phase 3	Spain	2015-10-12
Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma	Not yet recruiting	Phase 1	United States	2015-10-05
Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma	Not yet recruiting	Phase 1/Phase 2	United States	2015-09-24
Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells	Not yet recruiting	Phase 1	United States	2015-09-16
Lenalidomide Maintenance in Plasma Cell Myeloma	Recruiting	Phase 2	United States	2015-08-31
A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia	Recruiting	Phase 2	United States;Canada;United States	2015-08-25
Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple Myeloma	Recruiting		Germany	2015-08-24
Study of Ibrutinib in Combination With Rituximab and Lenalidomide	Recruiting	Phase 2	United States	2015-08-21
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma	Recruiting	Phase 1/Phase 2	United States	2015-08-18
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients.	Recruiting		The Netherlands	2015-08-12
A Study of Lenalidomide for Adult Histiocyte Disorders	Recruiting	Phase 2	United States;United States	2015-08-12
Study to Evaluate the Bioavailability and Food Effect Lenalidomide as an Oral Suspension	Completed	Phase 1	United States	2015-08-11
An Observational Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide.	Active, not recruiting			2015-08-06

注册题目	招募状态	试验分期	国家	登记时间
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone	Recruiting	Phase 3	United States	2015-08-04
BiRd vs. Rd as Initial Therapy in Multiple Myeloma	Active, not recruiting	Phase 3	United States	2015-08-04
Lenalidomide and dexamethasone (Ld) versus Clarithromycin / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as initial therapy in Multiple Myeloma.	Ongoing	phase 3	United States;Spain	2015-07-31
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma	Recruiting	Phase 1/Phase 2	United States	2015-07-06
A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U.	Recruiting		The Netherlands	2015-06-30
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma	Recruiting	Phase 3	Germany	2015-06-24
A clinical trial to study the effects of two drugs, Lenalidomide and Thalidomide given with low dose of Dexamethasone in patients with Multiple Myeloma		Phase 3	India	2015-06-23
Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.	Recruiting	Phase 2	United Kingdom	2015-06-01
A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma	Recruiting	Phase 2	Denmark;Finland;Norway;Sweden;Denmark;Finland;Norway;Sweden	2015-05-26
Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT	Recruiting	Phase 2	Germany	2015-05-20
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma	Recruiting	Phase 2	United States	2015-05-08
A 2-stage Phase II study of combination pomalidomide and low dose dexamethasone therapy in patients with relapsed myeloma previously treated with lenalidomide maintenance post Autologous Stem Cell Transplant (LEOPARD follow-on study)		Phase 2	Australia	2015-05-08
Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)	Recruiting	Phase 1	United States	2015-05-06

注册题目	招募状态	试验分期	国家	登记时间
A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM)	Recruiting	Phase 1	United States	2015-04-27
Bioequivalence of Lenalidomide capsules to healthy Chinese male volunteers in an open-label, randomised, single-dose, after the meal, two-way crossover study	Recruiting		China	2015-04-23
Bioequivalence of Lenalidomide capsules to healthy Chinese male volunteers in an open-label, randomised, single-dose,fasting,two-way crossover study	Recruiting		China	2015-04-23
Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT)	Recruiting	Phase 2	United States	2015-04-15
Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients	Recruiting	Phase 1		2015-04-13
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma	Recruiting	Phase 2	Spain	2015-03-29
Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma	Recruiting	Phase 3	Spain	2015-03-25
Phase1/2study evaluating safety and efficacy of bortezomib-lenalidomid-dexamethasone induction therapy followed by lenalidomide-dexamethasone consolidation and lenalidomide maintenance for newly diagnosed patients with multiple myeloma eligible for stem	Open public recruiting		Japan	2015-03-23
A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL	Recruiting	Phase 2	United States;Belgium;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;Belgiu	2015-03-13
Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients	Withdrawn	Phase 1/Phase 2		2015-03-10
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant	Recruiting	Phase 2	United States	2015-03-10
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-Bendamustine for Relapsed/Refractory FL Patients	Recruiting	Phase 3	Italy	2015-03-02



注册题目	招募状态	试验分期	国家	登记时间
A study of carfilzomib, lenalidomide and dexamethasone (KRd) plus high-dose therapy with melphalan-200 and autologous stem cell transplantation, followed by consolidation with KRd, and maintenance with lenalidomide and dexamethasone in patients with high	Ongoing	phase 2	Spain	2015-02-25
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme (Phase II)	Withdrawn	Phase 2	United States	2015-02-16
Evaluation of the Immune Restoration Potential Of Lenalidomide	Not yet recruiting	Phase 2	United States	2015-02-13
Lenalidomide and Obinutuzumab for Previously Untreated CLL	Not yet recruiting	Phase 1/Phase 2	United States	2015-02-13
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease	Recruiting	Phase 1	United States	2015-02-10
Expanded Access Treatment Protocol CA204-143	Available		United States;Puerto Rico;United States	2015-02-06
A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR	Recruiting		Turkey	2015-02-05
Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant	Terminated	Phase 2	United States	2015-01-28
A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U	Ongoing	phase 2	Netherlands	2015-01-26
Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year	Active, not recruiting	Phase 2	China	2015-01-23
Phase II study evaluating safety and efficacy of induction therapy with small-dose bortezomib, lenalidomide and dexamethasone combination for previously untreated symptomatic multiple myeloma	Open public recruiting		Japan;Japan	2015-01-19
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas	Recruiting	Phase 1/Phase 2	United States	2015-01-14
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment	Recruiting		Italy	2015-01-14
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM	Recruiting	Phase 2	United States	2015-01-13

注册题目	招募状态	试验分期	国家	登记时间
Clinical Trial to Determinate Dose, Security and Efficacy of Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma	Active, not recruiting	Phase 1/Phase 2	Spain	2015-01-09
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy	Recruiting	Phase 1	United States	2015-01-06
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma	Recruiting	Phase 1	United States	2014-12-23
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)	Recruiting	Phase 3	United States	2014-12-17
Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation	Recruiting	Phase 1	United States	2014-12-05
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis	Recruiting	Phase 2	United States	2014-12-03
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma	Not yet recruiting	Phase 1/Phase 2	United States	2014-10-30
Cord Blood Natural Killer (NK) Cells in Chronic Lymphocytic Leukemia (CLL)	Recruiting	Phase 1	United States	2014-10-29
Registry Study for Individuals With Del 5q Low or Intermediate-1 Risk MDS	Recruiting		Belgium;Denmark;France;Germany;Greece;Italy;Luxembourg;Norway;Spain;Sweden;United Kingdom;Belgium;D	2014-10-21
Trial in patients with newly diagnosed myeloma to evaluate the effect of elotuzumab in induction and consolidation therapy with bortezomib/lenalidomide/dexamethasone and in lenalidomide maintenance treatment	Ongoing	phase 3	Germany	2014-10-16
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients	Ongoing	phase 2	Belgium;Norway;Netherlands	2014-10-07
This protocol is a phase II randomized, multicenter study designed to assess the safety and the efficacy of different carfilzomib combinations in newly diagnosed MM patients eligible for autologous transplantation (ASCT).	Ongoing	phase 2	Italy	2014-10-03
A phase II trial of ibrutinib, lenalidomide and rituximab for patients with relapsed/refractory mantle cell lymphoma.	Ongoing	phase 2	Sweden	2014-09-26

注册题目	招募状态	试验分期	国家	登记时间
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML	Recruiting	Phase 1	United States	2014-09-26
Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma	Recruiting	Phase 2	United States	2014-09-26
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma	Recruiting	Phase 2	United States	2014-09-24
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma	Recruiting	Phase 2	United States	2014-09-03
Study to evaluate the efficacy of lenalidomide in combination with chemotherapy subcutaneous rituximab + miniCHOP for the treatment of B-cell lymphoma for patients of 80 years old or more.	Ongoing	phase 3	Portugal;France;Belgium	2014-09-02
This study is to assess the efficacy and safety of lenalidomide in combination with adriamycine and low dose dexamethasone in newly diagnosed patients with symptomatic multiple myeloma as well as to collect information regarding the effect of this regimen	Ongoing	phase 2	Greece	2014-09-01
Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)	Recruiting	Phase 2	United States	2014-08-22
Study of lenalidomide plus R-CHOP chemotherapy versus placebo plus R-CHOP chemotherapy in untreated diffuse large B-cell lymphoma	Ongoing	phase 3	Portugal;United States;Taiwan;Spain;Ireland;Turkey;United Kingdom;Italy;France;Czech Republic;Canada	2014-08-14
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma	Recruiting	Phase 3	United States;Australia;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Netherlands;New	2014-08-11
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas	Recruiting	Phase 1/Phase 2	United States	2014-08-05
STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS	Recruiting	Phase 3	Italy	2014-07-28

注册题目	招募状态	试验分期	国家	登记时间
Clinical trial to evaluate the treatment with a drug (lenalidomide) with the usually prescribed chemotherapy in patients diagnosed with diffuse large B-cell lymphoma (sort of blood cancer) which did not respond to previous treatments and who can not recei	Ongoing	phase 2	Spain	2014-07-22
Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)	Recruiting	Phase 1	United States	2014-07-22
Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial	Recruiting	Phase 2	Japan	2014-07-16
Pomalidomide for Lenalidomide for Failures	Recruiting	Phase 2	United States	2014-07-07
Evaluation of minimal residual disease,immune cells dynamics and quality of life in bortezomib based induction therapy followed by lenalidomide maintenance for newly diagnosed patients with multiple myeloma ineligible for stem cell transplantation.	Preinitiation		Japan;Japan	2014-07-01
Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagno	Recruiting	Phase 2	Italy	2014-06-30
A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.	Recruiting		Belgium;Denmark;Germany;Spain;United Kingdom;Belgium;Denmark;Germany;Spain;United Kingdom	2014-06-13
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients	Active, not recruiting	Phase 2	United States	2014-06-06
Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib	Recruiting	Phase 2	Singapore	2014-06-05
Safety and Efficacy of ibrutinib in combination with lenalidomide and rituximab in patients with previously treated Diffuse Large B-Cell Lymphoma	Ongoing	phase 2	France;United States;Canada;Belgium;Germany;United Kingdom	2014-06-03
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma	Withdrawn	Phase 3		2014-06-02
YCUMM-1401:Efficacy of VRD and Lenalidomide therapy after autologous stem cell transplantation for multiple myeloma patients	Open public recruiting	Phase 2	Japan;Japan	2014-06-01

注册题目	招募状态	试验分期	国家	登记时间
Phase II Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years With Alternating Bortezomib/dexamethasone (Bd) With Lenalidomide/dexamethasone (Ld).	Enrolling by invitation	Phase 2	Japan;Japan	2014-06-01
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Suspended	Phase 1	United States	2014-05-30
To study the Bioequivalence of following oral administration of domestic lenalidomide capsules in multiple myeloma patients	Recruiting		China	2014-05-19
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma	Recruiting	Phase 1/Phase 2	United States	2014-05-12
Phase II Study to evaluate efficacy and safety of Lenalidomide maintenance therapy for multiple myeloma patients under bortezomib treatment	Preinitiation	Phase 2	Japan;Japan	2014-05-05
Efficacy of therapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of lenalidomide + rituximab versus rituximab alone for older patients with mantle cell lymphoma			Portugal;France;Spain;Poland;Belgium;Netherlands;Germany;Italy	2014-05-05
Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in Remission	Recruiting	Phase 2	United States	2014-04-28
Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+	Recruiting	Phase 3	Belgium;France;Belgium;France	2014-04-23
Targeting Complete Response in Younger transplant-eligible Multiple myeloma patients with Bortezomib and Lenalidomide treatment after relapse with autologous stem cell transplantation	Open public recruiting		Japan;Japan	2014-04-14
Lenalidomide, subcutaneous bortezomib, and dexamethasone treatment for multiple myeloma	Ongoing	phase 2	Ireland	2014-04-10
Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM	Active, not recruiting	Phase 3	Belgium;France;Greece;Italy;Spain;Belgium;France;Greece;Italy;Spain	2014-04-09
Phase 2 study to evaluate the efficacy and the safety of clarithromycin, lenalidomide and dexamethasone (Personalized BiRd) for patients with relapsed or refractory multiple myeloma	Enrolling by invitation	Phase 2	Japan;Japan	2014-03-20
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma	Recruiting	Phase 1	United States	2014-03-11
Erismodegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma	Recruiting	Phase 2	United States	2014-03-11

注册题目	招募状态	试验分期	国家	登记时间
Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma	Suspended	Phase 1/Phase 2	United States	2014-02-28
Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma	Terminated	Phase 1/Phase 2	United States	2014-02-27
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma	Active, not recruiting	Phase 3	United States;Australia;Belgium;Canada;Denmark;France;Germany;Greece;Israel;Japan;Korea, Republic of	2014-02-27
A trial of combined azactidine and lenalidomide salvage therapy in patients with acute myeloid leukaemia who relapse after allogeneic stem cell transplantation	Recruiting		United Kingdom	2014-02-25
Phase I/II study of bortezomib plus Lenalidomide and dexamethasone (Once weekly VRd-21) for relapsed and/or refractory multiple myeloma (Once weekly VRd-21, I/II VRD for MM)	Completed	Phase 1/Phase 2	Japan	2014-02-15
Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Recruiting	Phase 1/Phase 2	United States	2014-02-10
Phase I/II trial of subcutaneous bortezomib plus lenalidomide combined with dexamethasone combination therapy for relapsed or refractory multiple myeloma patients	Open public recruiting	Phase 1/Phase 2	Japan	2014-02-08
Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)	Recruiting	Phase 2	Italy	2014-02-06
A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-Bendamustine for relapsed/refractory FL patients not el	Ongoing	phase 3	Italy	2014-01-27
A randomized trial of maintenance treatment between Lenalidomide and Placebo administred after a combination of Melphalan, Prednisone and Bortezomib as 1st intention in subjects diagnosed with multiple myeloma.	Ongoing	phase 3	France;Greece;Spain;Belgium	2014-01-20
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant	Recruiting	Phase 1/Phase 2	United States	2014-01-15

注册题目	招募状态	试验分期	国家	登记时间
Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid I	Recruiting		The Netherlands	2014-01-14
Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (Revlimid <sup>TM</sup> , CC-5013) in Plasma Cell Dyscrasias	Completed	Phase 2	United States	2014-01-14
A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)	Recruiting	Phase 1	United States;Canada;France;Spain;Canada;France;Spain;United States	2014-01-13
An open-label, multicenter, therapeutic effect and safety study of lenalidomide plus indexamethasone in refractory/relapsed MM	Recruiting		China	2014-01-09
Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma	Recruiting	Phase 1	United States	2013-12-19
Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer	Active, not recruiting	Phase 1	United States	2013-12-17
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL	Recruiting	Phase 2	United States	2013-12-03
Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Refractory Multiple Myeloma	Recruiting	Phase 1/Phase 2	United States	2013-11-26
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.	Recruiting	Phase 3	United States;Puerto Rico;United States	2013-11-22
Lenalidomide and GA101 in Relapsed Indolent Non-Hodgkin's Lymphoma	Recruiting	Phase 1/Phase 2	United States	2013-11-20
Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid I	Ongoing	phase 2/phase 3	Estonia;Finland;Belgium;Lithuania;Luxembourg;Austria;Norway;Germany;Netherlands;Switzerland;Sweden	2013-11-13
Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma	Terminated	Phase 1/Phase 2	United States	2013-11-08
A feasible study of lenalidomide for multiple myeloma in maintenance use at post autologous peripheral blood stem cell transplantation	Completed	Phase 1	Japan;Japan	2013-10-24
Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction	Recruiting	Phase 2	France	2013-10-16



注册题目	招募状态	试验分期	国家	登记时间
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma	Recruiting	Phase 1	United States	2013-10-10
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	Suspended	Phase 1	United States;Canada;United States	2013-09-27
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma	Recruiting	Phase 1	United States	2013-09-27
Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)	Recruiting		China	2013-09-18
Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma Following Lenalidomide Plus Low Dose Dexamethasone as Second Line Treatment.	Recruiting	Phase 2	United States;Canada;Puerto Rico;Canada;Puerto Rico;United States	2013-09-17
An open-label pilot clinical trial of MAGE-A3 and MAGE-C1 mRNA electroporated autologous dendritic cell vaccination in combination with lenalidomide maintenance therapy for multiple myeloma after first-line autologous stem cell transplantation.	Ongoing	phase 2	Belgium	2013-09-05
A phase I/II clinical study of deliverability and efficacy of high dose lenalidomide for the treatment of adult patients with acute lymphoblastic leukaemia		phase 1/phase 2	Australia	2013-09-05
Study of combination of rituximab and lenalidomide treatment in patients with recurrent or unresponsive indolent (slow growing) lymphoma who have been treated previously	Ongoing	phase 3	Portugal;United States;Spain;Turkey; Russian Federation;Israel;United Kingdom;Italy;France;Czech Republic	2013-08-29
Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma	Recruiting	Phase 2	France	2013-08-29
Lenalidomide/dexamethasone Salvage Therapy with stepwise Evaluation for Practical Dose Finding Study	Open public recruiting	Phase 2	Japan;Japan	2013-08-24
Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)	Recruiting		United States	2013-08-20
Treatment Optimization in Patients With Untreated Multiple Myeloma	Recruiting	Phase 2/Phase 3	Germany	2013-08-13
Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)	Recruiting	Phase 2	United States	2013-08-13



注册题目	招募状态	试验分期	国家	登记时间
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma	Recruiting	Phase 2	United States	2013-08-07
Lenalidomide and Ipilimumab Post Allo or Auto Stem Cell Transplantation (SCT)	Recruiting		United States	2013-08-07
Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old	Recruiting	Phase 3	Spain	2013-07-30
Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)	Active, not recruiting	Phase 2	France	2013-07-29
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Active, not recruiting	Phase 1	United States	2013-07-17
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Recruiting	Phase 1	United States	2013-06-24
Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma	Active, not recruiting	Phase 1/Phase 2	United States	2013-06-13
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL	Recruiting	Phase 3	Belgium;France;Germany;Portugal;Belgium;France;Germany;Portugal	2013-05-24
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma	Active, not recruiting	Phase 0	United States	2013-05-20
Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma	Recruiting	Phase 2	United States	2013-05-14
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma	Recruiting	Phase 2	United States	2013-05-14
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma	Recruiting	Phase 3	United States	2013-05-06
Front-line therapy with Carfilzomib, Lenalidomide, and Dexamethasone (CRd) induction followed by autologous stem cell transplantation, CRd consolidation and Lenalidomide maintenance in Newly Diagnosed Multiple Myeloma Patients ≥65 years old : a phase II	Ongoing	phase 2	France	2013-04-22
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma	Active, not recruiting	Phase 1/Phase 2	United States	2013-04-19

注册题目	招募状态	试验分期	国家	登记时间
Phase II study evaluating the efficacy of Lenalidomide in association with Rituximab in refractory or relapse of primary central nervous system lymphoma	Ongoing	phase 2	France	2013-04-18
A study to see the response of drugs Melphalan,Prednisolone and lenalidomide in the treatment of elderly patients,diagnosed as Multiple Myeloma(A type of cancer)	Recruiting		India	2013-04-17
Evaluation of the Feasible dose of Lenalidomide as maintenance therapy after Allogeneic hematopoietic stem cell Transplantation for multiple myeloma	Open public recruiting	Phase 1/Phase 2	Japan;Japan	2013-04-11
Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma	Active, not recruiting	Phase 1	United States	2013-04-09
Lenalidomide Plus Rituximab (R) in Non Follicular NHL	Active, not recruiting	Phase 2	Italy	2013-04-05
Pilot Study Immunomonitoring Natural Killers Cells in Patients With Myeloid Malignancies Treated With Lenalidomide	Completed		France	2013-04-03
A Phase II Study of Lenalidomide Induction, Autologous Peripheral Stem Cell Transplant and Adjuvant Vaccination with Autologous Dendritic Cells and Lenalidomide Maintenance in Multiple Myeloma.		Phase 2	Australia	2013-03-28
A phase 2 study of cyclophosphamide, lenalidomide and dexamethasone (CRD) for patients with relapsed/refractory multiple myeloma	Open public recruiting	Phase 2	Japan;Japan	2013-03-28
Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma	Active, not recruiting	Phase 2	United States;Canada;United States	2013-03-20
Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome	Active, not recruiting	Phase 2	China	2013-03-14
Oral Azacitidine, Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma		Phase 1	Australia	2013-03-08
Investigation of the maximum optimal dosage and efficacy of lenalidomide for the treatment of relapsed and refractory multiple myeloma.	Open public recruiting		Japan;Japan	2013-03-06
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide	Active, not recruiting	Phase 2	United States	2013-02-14

注册题目	招募状态	试验分期	国家	登记时间
A randomised study to test the effectiveness of LEnalidomide plus rituximab, GEMcitabine and methylprednisolone (LR-GEM) in comparison to rituximab, gemcitabine, methylprednisolone and cisplatin (R-GEM-P) in treatment of Diffuse Large B-cell lymphoma (DLB)	Ongoing	phase 2	United Kingdom	2013-02-11
Analysis of efficacy and immunomodulatory activity of lenalidomide alone in relapse and refractory multiple myeloma	Open public recruiting	Phase 2	Japan;Japan	2013-02-01
Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)	Active, not recruiting	Phase 2	United States	2013-01-15
Lenalidomide and Eltrombopag Olamine in Treating Patients With Symptomatic Anemia in Low or Intermediate Myelodysplastic Syndrome	Recruiting	Phase 2	United States	2013-01-15
Minimal residual disease monitoring in patients with multiple myeloma that they have obtain a good response to the maintenance treatment with revlimid	Ongoing	phase 2	Italy	2013-01-11
Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia	Terminated	Phase 2	United States	2013-01-07
Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma	Recruiting	Phase 1/Phase 2	United States	2012-12-19
A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan	Completed		Taiwan	2012-12-14
Ipilimumab and Lenalidomide in Advanced Cancer	Recruiting	Phase 1	United States;United States	2012-12-13
Lenalidomide After Allo Transplant	Terminated	Phase 1	United States	2012-12-12
SAR650984, Lenalidomide, and Dexamethasone in Combination in RRMM Patients	Active, not recruiting	Phase 1	United States	2012-12-10
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies	Completed	Phase 1/Phase 2	United States	2012-12-05
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)	Withdrawn	Phase 2	United States	2012-11-27
Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL	Recruiting	Phase 2	Italy	2012-11-27
Safety and efficacy of lenalidomide cyclophosphamide and dexamethasone (RCd) therapy in Japanese elderly patients with multiple myeloma, a phase I/II study	Open public recruiting	Phase 1/Phase 2	Japan;Japan	2012-11-24

注册题目	招募状态	试验分期	国家	登记时间
An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)	Recruiting	Phase 1/Phase 2	United States	2012-11-21
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma	Active, not recruiting	Phase 4	United States	2012-11-19
Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia	Recruiting	Phase 2	United States	2012-11-16
Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma	Active, not recruiting	Phase 1	United States;Austria;United States;Germany	2012-11-14
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma	Recruiting	Phase 1/Phase 2	United States	2012-11-09
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)	Recruiting	Phase 2	United States	2012-11-09
A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma	Active, not recruiting	Phase 2	Japan	2012-11-07
Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide	Active, not recruiting	Phase 2	United States	2012-11-06
Study to assess the safety and efficacy of Lenalidomide and Ofatumumab combination (Lenofa) in chronic lymphocytic leukemia (CLL) patients relapsed or refractory after fludarabine containing regimens	Completed	phase 2	Italy	2012-10-31
MLN 9708 With Lenalidomide as Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma Patients	Active, not recruiting	Phase 2	United States	2012-10-29
A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma	Active, not recruiting	Phase 1	France	2012-10-29
Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.	Active, not recruiting	Phase 2	France;Monaco;France;Monaco	2012-10-23
Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males	Completed	Phase 1	United States	2012-10-22
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma	Completed	Phase 1/Phase 2	United States	2012-10-18

注册题目	招募状态	试验分期	国家	登记时间
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma	Recruiting	Phase 1	United States;Canada;United States	2012-10-18
Phase II study of bortezomib-melphalan-prednisolone induction therapy followed by lenalidomide-plus-dexamethasone consolidation and lenalidomide maintenance for newly diagnosed patients with multiple myeloma ineligible for stem cell transplantation.	Open public recruiting	Phase 2	Japan;Japan	2012-10-05
A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma	Active, not recruiting	Phase 2	Japan	2012-10-01
A forward-looking study to assess disease remission in patients with newly diagnosed blood cancer (multiple myeloma) who will be treated with a combination of three drugs followed by transplantation of own blood stem cells and maintenance therapy with on	Ongoing	phase 2	Finland	2012-09-26
Low dose of lenalidomide and dexamethasone therapy for elderly multiple myeloma	Open public recruiting		Japan;Japan	2012-09-14
Feasibility and dose-finding study of fixed-dose lenalidomide in conjunction with increasing doses of methotrexate, leucovorin, cytarabine and rituximab in relapsed or refractory CD20-positive aggressive lymphomas	Ongoing	phase 1/phase 2	Germany	2012-09-13
Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)	Completed	Phase 1/Phase 2	Germany	2012-09-11
the study of the influence of the harvest of the CD34 positive peripheral blood stem cell of the induction therapy using lenalidomide,cyclophosphamide,dexamethasone(RCd therapy) for untreated symptomatic multiple myeloma	Open public recruiting	Phase 2	Japan;Japan	2012-09-07
Lenalidomide Plus Chemotherapy for AML	Completed	Phase 1	United States	2012-09-02
Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance	Recruiting	Phase 2	Canada	2012-08-29
Study to determine the recommended dose, the safety and the efficacy of lenalidomide administered in association with obinutuzumab (GA101) for the treatment of relapsed/refractory B-cell Lymphoma.	Ongoing	phase 1/phase 2	France	2012-08-28
Lenalidomide Maintenance Therapy for Multiple Myeloma	Active, not recruiting	Phase 2	United States	2012-08-25
Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome	Active, not recruiting	Phase 2	Korea, Republic of	2012-08-22

注册题目	招募状态	试验分期	国家	登记时间
S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma	Recruiting	Phase 1/Phase 2	United States	2012-08-16
To investigate the efficacy and safety of lenalidomide and dexamethasone for elderly or frail patients with relapsed/refractory multiple myeloma	No longer recruiting		Japan;Japan	2012-08-01
Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma	Recruiting	Phase 1/Phase 2	Italy	2012-07-31
Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)	Active, not recruiting	Phase 2	United States	2012-07-24
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia	Completed		United States	2012-07-23
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance	Withdrawn	Phase 2	United States	2012-07-19
Phase 1 Pharmacokinetic Study of Oral IXAZOMIB Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma	Active, not recruiting	Phase 1	Hong Kong;Korea, Republic of;Singapore;Hong Kong;Korea, Republic of;Singapore	2012-07-18
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma	Active, not recruiting	Phase 1	United States	2012-07-17
POEMS Syndrome Treatment With Lenalidomide	Recruiting	Phase 2	France	2012-07-05
Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia	Completed	Phase 1	United States	2012-06-22
Phase II study evaluating safety and efficacy of maintenance therapy with bortezomib, lenalidomide and dexamethasone for multiple myeloma	Completed		Japan;Japan	2012-06-22
BENDAMUSTINE, LENALIDOMIDE AND RITUXIMAB (R2-B)COMBINATION AS A SECOND-LINE THERAPY FOR FIRST RELAPSED-REFRACTORY MANTLE CELL LYMPHOMAS: A PHASE II STUDY	Ongoing	phase 2	Italy	2012-06-08
Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma	Terminated	Phase 2	United States	2012-06-08
Phase I Study of Lenalidomide in Patients With Acute Leukemia	Recruiting	Phase 1	United States	2012-06-06



注册题目	招募状态	试验分期	国家	登记时间
A Phase II Study exploring the feasibility of Azacitidine and Lenalidomide use (combination vs sequential treatment) for Higher-Risk Myelodysplastic Syndromes (MDS) (IPSS Risk: High or INT-2)	Ongoing	phase 2	Italy	2012-05-24
Fludarabine/Rituximab combined with escalating doses of Lenalidomide in untreated chronic lymphocytic leukemia (CLL)	Completed	phase 1/phase 2	Austria	2012-05-22
Safety and efficacy of lenalidomide and prednisone therapy in Japanese elderly patients with multiple myeloma, a phase II study	Open public recruiting	Phase 2	Japan;Japan	2012-05-20
Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue	Completed	Phase 2	Austria	2012-05-18
Safety and efficacy of lenalidomide, dexamethasone, and clarithromycin therapy in Japanese patients with multiple myeloma, a phase I/II study	Open public recruiting		Japan;Japan	2012-05-11
Low-dose lenalidomide plus dexamethasone after initial therapy with melphalan and prednisone in myeloma patients ineligible for stem cell transplantation	No longer recruiting		Japan;Japan	2012-05-05
Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma	Completed	Phase 2	China	2012-05-04
Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide	Terminated	Phase 1	United States	2012-05-04
To investigate the efficacy and safety of Bortezomib and Lenalidomide as induction, consolidation and maintenance therapy for untreated multiple myeloma patients eligible for autologous stem cell transplantation.	No longer recruiting		Japan;Japan	2012-04-27
Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma	Recruiting	Phase 1/Phase 2	Belgium;France;Belgium;France	2012-04-20
The efficacy, safety, and the predictive factors of efficacy of low dose Lenalidomide plus Dexamethasone consolidation therapy followed by very low dose Lenalidomide maintenance therapy for multiple myeloma.	Enrolling by invitation	Phase 2	Japan;Japan	2012-04-19
Lenalidomide as Consolidation and Maintenance in Adults >= 60 Years of Age With AML Following Standard Induction	Recruiting	Phase 1	United States	2012-04-13
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma	Active, not recruiting	Phase 1	United States	2012-04-11
Maintenance Lenalidomide in Lymphoma	Recruiting	Phase 1/Phase 2	United States;United States	2012-04-10

注册题目	招募状态	试验分期	国家	登记时间
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma	Active, not recruiting	Phase 2	United States	2012-04-05
A PHASE II STUDY OF CYCLOPHOSPHAMIDE IN MULTIPLE MYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURING LENALIDOMIDE-DEXAMETHASONE TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA	Ongoing	phase 2	Italy	2012-04-02
Lenalidomide with epigenetic therapy in relapsed or refractory Acute Myeloid Leukaemia (AML)-Phase II		Phase 2	Australia;New Zealand	2012-03-20
Lenalidomide with epigenetic therapy in relapsed or refractory Acute Myeloid Leukaemia (AML)-Phase I		Phase 1	Australia;New Zealand	2012-03-16
BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS.	Ongoing	phase 2	Italy	2012-03-14
A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy	Recruiting	Phase 3	Germany	2012-03-14
Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma	Completed	Phase 2	France;France	2012-03-12
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma	Recruiting	Phase 2	United States;Australia;Canada;New Zealand;Australia;Canada;New Zealand;United States	2012-03-10
Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma	Recruiting	Phase 1/Phase 2	Italy;Switzerland;Italy;Switzerland;Italy;Switzerland	2012-03-08
BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma	Active, not recruiting	Phase 1/Phase 2	United States	2012-03-08
Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma	Active, not recruiting	Phase 2	Taiwan	2012-03-01
MALT-2		phase 2	Austria	2012-02-28
Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer	Completed	Phase 1/Phase 2	Sweden	2012-02-28
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma	Recruiting	Phase 1	United States	2012-02-27



注册题目	招募状态	试验分期	国家	登记时间
Daratumumab Open label, dose-escalation safety study in Combination with Lenalidomide and Dexamethasone in Patients with multiple myeloma	Ongoing	phase 1/phase 2	France;United States;Denmark;Netherlands;Italy;United Kingdom	2012-02-16
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma	Recruiting	Phase 2	United States	2012-02-16
Lenalidomide/Bortezomib/Dexamethasone & CINTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)	Completed	Phase 1/Phase 2	United States	2012-02-09
Efficacy and cytokines of lenalidomide therapy in Japanese patients with relapsed or refractory multiple myeloma	Enrolling by invitation		Japan;Japan	2012-02-02
Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These D	Recruiting	Phase 2	Italy	2012-01-27
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia	Active, not recruiting	Phase 2/Phase 3	United States;Canada;United States;Canada	2012-01-27
Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma	Completed	Phase 3	Saudi Arabia	2012-01-23
Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)	Recruiting	Phase 2	Belgium;France;Belgium;France	2012-01-20
Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma	Active, not recruiting	Phase 2	United States	2012-01-18
ACE-011 With Lenalidomide+Dexamethasone for Relapsed/Refractory Multiple Myeloma	Recruiting	Phase 1	United States	2012-01-08
Vorinostat, Lenalidomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalidomide Containing Regimens	Active, not recruiting	Phase 1/Phase 2	United States	2011-12-27
Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)	Active, not recruiting	Phase 2	United States	2011-12-20
Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)	Active, not recruiting	Phase 2	United States	2011-12-16

注册题目	招募状态	试验分期	国家	登记时间
Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy	Withdrawn	Phase 2	Italy	2011-12-16
Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma	Recruiting	Phase 1/Phase 2	United States	2011-11-28
ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma	Active, not recruiting	Phase 2	Denmark	2011-11-21
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma	Active, not recruiting	Phase 3	United States;Japan;United States;United States;Japan;United States	2011-11-18
Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia	Terminated	Phase 2	United States	2011-10-28
Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance	Active, not recruiting	Phase 2	United States;United States	2011-10-28
STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL).	Ongoing	phase 2	Belgium	2011-10-24
Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)	Active, not recruiting	Phase 2	United Kingdom	2011-10-18
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma	Active, not recruiting	Phase 2	United States	2011-10-14
Clinical, open and multicentric phase II trial to evaluate the efficacy and safety of Bendamustine in combination with Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line therapy for the multiple myeloma for patients with relapsed or non-respond	Completed	phase 2	Germany;Switzerland	2011-10-11
Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)	Active, not recruiting	Phase 2	United States	2011-10-03
A study to evaluate efficacy and safety of azacitidine alone or in combination with lenalidomide in patients with advanced cancer in the bone marrow or in the blood with a defective chromosome 5	Ongoing	phase 2	Finland;Denmark;Norway;Sweden	2011-09-27
Azacitidine + Lenalidomide Combo in the Elderly Previously Treated Acute Myeloid Leukemia (AML) & High-Risk Myelodysplastic Syndromes (MDS)	Terminated	Phase 2	United States	2011-09-23

注册题目	招募状态	试验分期	国家	登记时间
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients	Recruiting	Phase 1	United States	2011-09-22
Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome	Recruiting	Phase 1	United States	2011-09-12
Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line	Completed		Sweden	2011-09-07
An Open-Label Phase II Study of the Safety and Efficacy of Doxorubicin and Cyclophosphamide in Combination with Bortezomib, Lenalidomide, and Dexamethasone for Treatment of Patients with Newly Diagnosed Multiple Myeloma	Ongoing	phase 2	Denmark	2011-09-05
Efficacy and safety of first-line therapy with chlorambucil, rituximab and lenalidomide (Revlimid®) (CR2) in elderly patients and young frail patients with advanced Chronic Lymphocytic Leukemia (CLL): A phase II trial.			The Netherlands	2011-09-02
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma	Active, not recruiting	Phase 1	United States	2011-09-02
Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma	Completed	Phase 1	France	2011-08-22
ReBeL study: A randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients = 18 years with relapsed follicular lymphoma. A HOVON/GLSG study.			The Netherlands	2011-08-18
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome	Terminated	Phase 2	United States	2011-08-18
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant	Terminated	Phase 2	United States	2011-08-15
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma	Recruiting	Phase 2	United States;Canada;United States;Canada	2011-08-11
A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma	Active, not recruiting	Phase 1/Phase 2	Italy	2011-08-03
Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients	Active, not recruiting	Phase 2	United States	2011-07-23

注册题目	招募状态	试验分期	国家	登记时间
Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia	Terminated	Phase 2	United States	2011-07-20
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase	Ongoing	phase 3	Germany	2011-07-13
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function	Active, not recruiting	Phase 1	United States	2011-07-12
A randomized phase II study for evaluation of T cell depleted non myeloablative allogeneic stem cell transplantation followed by early consolidation with lenalidomide or lenalidomide combined with bortezomib and subsequent DLI for patients with multiple m	Recruiting		The Netherlands	2011-06-29
Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma	Completed	Phase 1/Phase 2	United States	2011-06-27
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma	Active, not recruiting	Phase 2	United States	2011-06-22
Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer	Completed	Phase 1	United States	2011-06-20
A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes	Terminated	Phase 2	United States	2011-06-17
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis	Active, not recruiting	Phase 2	United States	2011-06-14
Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma	Terminated	Phase 2	United States	2011-06-13
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer	Active, not recruiting	Phase 2	United States	2011-06-13
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)	Completed	Phase 1	United States	2011-06-12
A phase II study of lenalidomide and prednisolone as post-autologous stem cell transplant (ASCT) maintenance therapy for patients with Multiple Myeloma incorporating residual disease monitoring.		Phase 2	Australia	2011-06-09
A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia in Elderly Subje	Active, not recruiting	Phase 2	United States;Canada;United States	2011-05-19

注册题目	招募状态	试验分期	国家	登记时间
Phase I/II Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma	Active, not recruiting	Phase 1/Phase 2	United States	2011-05-16
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors	Active, not recruiting	Phase 1	United States	2011-05-11
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma	Completed	Phase 1	United States	2011-05-11
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Active, not recruiting	Phase 2	United States;United States	2011-05-10
Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission	Active, not recruiting	Phase 2	United States	2011-05-05
CEP-18770 in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma	Terminated	Phase 1/Phase 2	United States;New Zealand;United States;New Zealand	2011-05-04
Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma	Terminated	Phase 1	United States	2011-05-04
Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma	Terminated	Phase 1/Phase 2	United States	2011-04-21
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma	Active, not recruiting	Phase 3	United States;Australia;Austria;Belgium;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Israel;	2011-04-13
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL	Active, not recruiting	Phase 1	United States	2011-04-11
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma	Active, not recruiting	Phase 2	United States	2011-03-24
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma	Recruiting	Phase 2	Puerto Rico	2011-03-01
Revlimid, Endoxan, Prednisone Evaluation After prior revlimid Treatment (REPEAT): A phase 1 and phase 2 study of lenalidomide (Revlimid) in combination with cyclophosphamide (endoxan) and prednisone (REP) in relapsed/refractory multiple myeloma	Ongoing	phase 1/phase 2	Netherlands	2011-02-23
Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide	Terminated	Phase 3	United States	2011-02-22

注册题目	招募状态	试验分期	国家	登记时间
Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)	Active, not recruiting	Phase 1/Phase 2	United States	2011-02-18
Phase II trial of ofatumumab, dexamethasone and lenalidomide for high-risk CLL (NCRI CLL210) - CLL210 (OfaDexRev)	Temporarily Halted	phase 2	United Kingdom	2011-02-16
Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy.	Ongoing	phase 2	Finland;Switzerland; Sweden	2011-02-14
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma	Recruiting	Phase 1/Phase 2	United States	2011-02-11
Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma	Recruiting	Phase 2	United States	2011-02-04
To examine the safety and tolerability of lenalidomide in combination with 5-azacitidine as maintenance therapy for Acute Myeloid Leukaemia (AML) in complete remission after intensive chemotherapy.		phase 1/phase 2	Australia	2011-02-01
Lenalidomide in Kaposi Disease Associated With HIV Infection	Terminated	Phase 2	France	2011-01-21
Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)	Completed	Phase 1/Phase 2	Italy	2011-01-13
Lenalidomide in HTLV-1 Adult T-Cell Leukemia	Completed	Phase 2	United States	2011-01-10
Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia	Withdrawn	Phase 2	United States	2011-01-05
Randomized phase II Trial comparing Lenalidomide with lowdose dexamethasone versus Lenalidomide in Second Line Multiple Myeloma (MM)	Ongoing	phase 2	Denmark;Sweden	2010-12-27
(A Phase 2) STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE (Rd) FOLLOWED BY RITUXIMAB, AUTOGRAFT AND LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED WALDESTROM MACROGLOBULINEMIA SUBJECTS - ND	Prematurely Ended	phase 2	Italy	2010-12-22
Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients	Recruiting	Phase 2	Canada	2010-12-13
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers	Active, not recruiting	Phase 1	United States	2010-12-03
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer	Active, not recruiting	Phase 1	United States	2010-12-03



注册题目	招募状态	试验分期	国家	登记时间
Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma	Active, not recruiting	Phase 2	United States	2010-11-19
Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL	Active, not recruiting	Phase 1/Phase 2	United States	2010-11-15
Study Examining the Combination of Lenalidomide and Azacitidine for Relapsed/Refractory CLL and SLL	Terminated	Phase 2	United States	2010-11-15
Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents	Completed	Phase 2	United States	2010-11-15
Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Active, not recruiting	Phase 1	United States	2010-11-12
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma	Active, not recruiting	Phase 3	Israel;Italy;Japan;Pol and;Puerto Rico;Romania;Spain; Switzerland;Turkey;U nited Kingdom;United States;	2010-11-08
Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone	Active, not recruiting	Phase 1	Japan	2010-11-04
MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry	Completed		Italy	2010-10-29
Phase II study of lenalidomide consolidation/maintenance therapy after autologous stem cell transplantation in patients with symptomatic multiple myeloma.	Completed		Japan;Japan	2010-10-20
Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas	Active, not recruiting	Phase 1	United States	2010-10-15
Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)	Terminated	Phase 2	United States	2010-10-14
Study of Everolimus (RAD001) in Combination With Lenalidomide	Active, not recruiting	Phase 1	United States	2010-10-08
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse	Completed	Phase 1	United States	2010-10-06
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma	Recruiting	Phase 2	United States	2010-10-06

注册题目	招募状态	试验分期	国家	登记时间
Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment	Completed	Phase 1/Phase 2	Spain	2010-09-30
A Study of IXAZOMIB Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma	Active, not recruiting	Phase 1/Phase 2	United States	2010-09-24
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65	Recruiting	Phase 3	United States;France	2010-09-23
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer	Active, not recruiting	Phase 1/Phase 2	United States;Canada;United States	2010-09-22
Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma	Active, not recruiting	Phase 0	United States	2010-09-21
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer	Terminated	Phase 1	United States	2010-09-14
Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide	Terminated	Phase 1	United States	2010-09-09
A study of the effect of donor stem cell transplantation followed by treatment with lenalidomide or lenalidomide with bortezomib and subsequent DLI for patients with a relapse or progression following first line therapy	Temporarily Halted	phase 2	Netherlands	2010-08-30
Phase II Study of the Adjunctive Use of Lenalidomide in Patients Undergoing Reduced Intensity Conditioning Allogeneic Transplantation for Multiple Myeloma - Post Transplant Lenalidomide for Multiple Myeloma (Version 1)	Ongoing	phase 2	United Kingdom	2010-08-18
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)	Completed	Phase 1	United States	2010-08-13
Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma	Withdrawn	Phase 1/Phase 2	United States	2010-08-10
A phase I/II safety and efficacy trial of a combination of bendamustine, rituximab and lenalidomide (BRL) in patients with relapsed or refractory chronic lymphocytic leukemia	Completed	phase 1/phase 2	Germany	2010-08-10
High-dose lenalidomide maintenance therapy in adult acute myeloid leukaemia (AML)		Phase 1	Australia;New Zealand	2010-08-02
LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)	Terminated	Phase 4	Spain	2010-07-29
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma	Recruiting	Phase 2/Phase 3	United States;Ireland;Puerto Rico;Ireland;Puerto Rico;United States	2010-07-23



注册题目	招募状态	试验分期	国家	登记时间
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma	Completed	Phase 1	Japan	2010-07-22
Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors	Recruiting	Phase 1/Phase 2	Austria	2010-07-19
Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide	Active, not recruiting	Phase 1/Phase 2	Italy	2010-07-16
Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma	Completed	Phase 2	United States	2010-07-07
Lenalidomide and Paclitaxel in Advanced Solid Tumors	Active, not recruiting	Phase 1	Italy;Switzerland;Italy;Switzerland	2010-06-30
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma	Active, not recruiting	Phase 1/Phase 2	United States	2010-06-30
Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma	Active, not recruiting	Phase 2	United States	2010-06-15
Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma	Active, not recruiting	Phase 1/Phase 2	United States	2010-06-10
A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myeloma	Ongoing	phase 3	Serbia;Portugal;Estonia;Slovakia;Greece;Ireland;Luxembourg;Israel;Switzerland;Italy;Denmark;Australi	2010-05-27
Cetuximab and Lenalidomide in Head and Neck	Completed	Phase 2	United States	2010-05-27
Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia	Completed	Phase 1	United States	2010-05-26
Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma	Recruiting	Phase 2	United States	2010-05-25
Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS	Active, not recruiting	Phase 2	United States	2010-05-25
Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia	Active, not recruiting	Phase 2	Canada	2010-05-19
Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer	Terminated	Phase 1	United States	2010-05-18

注册题目	招募状态	试验分期	国家	登记时间
Lenalidomide for Lean Body Mass and Muscle Strength in Inflammatory Cancer Cachexia Syndrome	Recruiting	Phase 1/Phase 2	Switzerland	2010-05-12
Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab	Completed	Phase 2	United States	2010-05-04
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	Terminated	Phase 1	United States	2010-04-30
A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse	Completed	Phase 1/Phase 2	France	2010-04-26
Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL	Recruiting	Phase 2	United States	2010-04-23
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)	Active, not recruiting	Phase 3	United States	2010-04-21
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB = 66 years and very poor risk AML = 18 years.	Recruiting		The Netherlands	2010-04-19
Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP	Active, not recruiting	Phase 3	Australia;Austria;Belgium;France;Israel;Poland;Portugal;Spain;Switzerland;Australia;Austria;Belgium;	2010-04-08
Lenalidomide and 5azacitidine treatment versus 5azacitidine alone in patients with the blood cancers myelodysplastic syndrome or acute myeloid leukaemia		Phase 2	Australia;New Zealand	2010-04-01
Study of lenalidomide to evaluate safety and effectiveness in patients with Diffuse Large B Cell Lymphoma	Ongoing	phase 2/phase 3	France;Czech Republic;Spain;Austria;Australia;Italy;United Kingdom;Sweden	2010-04-01
A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 6	Ongoing	phase 3	Belgium;France	2010-03-30
Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer	Active, not recruiting	Phase 1/Phase 2	United States	2010-03-24
Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients	Active, not recruiting	Phase 3	Italy	2010-03-24

注册题目	招募状态	试验分期	国家	登记时间
Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m <sup>2</sup> ) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects	Active, not recruiting	Phase 3	Italy	2010-03-22
Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma	Recruiting	Phase 3	Germany	2010-03-18
Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q	Active, not recruiting	Phase 2	France;France	2010-03-16
Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma	Active, not recruiting	Phase 3	United States;Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;It	2010-03-02
Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q	Completed	Phase 2	Germany	2010-03-02
Lenalidomide and High-Dose Melphalan	Completed	Phase 1/Phase 2	United States	2010-03-02
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	Active, not recruiting	Phase 1/Phase 2	United States	2010-02-25
Randomisierte Phase III Studie für Patienten mit Multiplem Myelom zur Untersuchung zweier Therapieschemata einer Bortezomib-basierten Induktionstherapie und einer Lenalidomid-Konsolidierungstherapie gefolgt von einer Erhaltungstherapie mit Lenalidomid	Ongoing	phase 3	Germany	2010-02-23
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma	Active, not recruiting	Phase 1/Phase 2	United States	2010-02-23
A PHASE III MULTICENTER, RANDOMIZED STUDY WITH LENALIDOMIDE (Revlimid) MAINTENANCE VERSUS OBSERVATION AFTER INTENSIFIED INDUCTION REGIMEN CONTAINING RITUXIMAB FOLLOWED BY HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION AS FIRST LINE TREA	Ongoing	phase 3	Portugal;Italy	2010-02-04
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)	Completed	Phase 1	United States	2010-02-02
A Phase I/II Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukemia	Completed	phase 1/phase 2	Austria	2010-01-28

注册题目	招募状态	试验分期	国家	登记时间
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma	Active, not recruiting	Phase 1/Phase 2	United States	2010-01-26
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma	Active, not recruiting	Phase 1/Phase 2	United States	2010-01-25
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma	Withdrawn	Phase 2	United States	2010-01-22
Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma	Active, not recruiting	Phase 2	United States;United States	2010-01-21
The research project is trying to find out if we can improve the results of best available chemotherapy for Chronic Lymphocytic Leukaemia (CLL) by the addition of a new drug called lenalidomide.		Phase 3	Australia;New Zealand	2010-01-19
Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome	Recruiting	Phase 2	Israel	2010-01-19
Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study	Recruiting	Phase 1/Phase 2	United States	2010-01-19
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma.	Prematurely Ended	phase 3	France;Finland;Belgium;Spain;Denmark;Austria;Netherlands;Germany;United Kingdom;Switzerland	2010-01-18
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma	Active, not recruiting	Phase 1/Phase 2	United States	2010-01-14
Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma	Active, not recruiting		United States	2010-01-14
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma	Terminated	Phase 1	United States	2010-01-08
Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma	Completed	Phase 1	United States	2010-01-04
Randomisierte, offene, multizentrische Phase III Studie zum Vergleich von Lenalidomid/Dexamethason versus Lenalidomid/Dexamethason mit anschließender autologer Blutstammzelltransplantation und Lenalidomid Erhaltungstherapie für Patienten mit rezidiertem	Ongoing	phase 3	Germany	2009-12-30

注册题目	招募状态	试验分期	国家	登记时间
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)	Completed	Phase 1/Phase 2	United States	2009-12-23
Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy	Recruiting	Phase 1/Phase 2	United States	2009-12-17
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia	Completed	Phase 1	Spain	2009-12-17
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia	Recruiting		United States	2009-12-15
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma	Active, not recruiting	Phase 1/Phase 2	United States	2009-12-08
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q	Active, not recruiting	Phase 3	United States;Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Israel;Italy;Japan;Poland	2009-12-08
Phase I/II study of lenalidomide and Cetuximab in patients with advanced solid tumors	Prematurely Ended	phase 1/phase 2	Austria	2009-11-25
A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).	Terminated	Phase 3	United States;Czech Republic;France;Germany;Israel;Italy;Poland;Portugal;Puerto Rico;Russian Federation	2009-11-25
Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma	Completed	Phase 1/Phase 2	Germany	2009-11-24
Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002	Ongoing	phase 2	Italy	2009-11-17
Azacytidine and Lenalidomide for Acute Myeloid Leukemia	Completed	Phase 1/Phase 2	United States	2009-11-17

注册题目	招募状态	试验分期	国家	登记时间
The GMMG-HD5 trial: bortezomib-based induction prior to high dose therapy and autologous stem cell transplantation followed by lenalidomide-based consolidation and maintenance therapy in patients with multiple myeloma	Recruiting		France;Germany	2009-11-11
Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age	Completed	Phase 2	United States	2009-11-09
Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial	Recruiting	Phase 1/Phase 2	Germany	2009-11-06
Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid®) with Rituximab, Dexamethason, High-dose ARA-C and Cisplatinum (R2-DHAP) - R2-DHAP	Prematurely Ended	phase 1/phase 2	Germany	2009-11-04
Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia	Recruiting	Phase 1/Phase 2	United States	2009-10-28
Lenalidomide and Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL)	Active, not recruiting	Phase 2	United States	2009-10-26
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma	Recruiting	Phase 1/Phase 2	Germany	2009-10-23
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant	Completed	Phase 2	United States	2009-10-19
A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, FIRST LINE MAINTENANCE STUDY OF LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH MANTLE-CELL LYMPHOMA - The RENEW trial		Phase 3	Portugal;United Kingdom;Germany;Czech Republic;France;Spain;Italy	2009-10-16
Efficacy and Safety of Lenalidomide for Treatment of Autistic Spectrum Disorders	Completed	Phase 2	United States	2009-10-15
A single arm phase II study to investigate the use of Lenalidomide in the treatment of patients with early stage CLL associated with poor prognostic factors. - RESPeCT: Revlimid Early Stage Poor prognosis CLL Trial	Ongoing	phase 2	United Kingdom	2009-10-14
IMGN901 in Combination With Lenalidomide and Dexamethasone	Completed	Phase 1	United States	2009-10-07

注册题目	招募状态	试验分期	国家	登记时间
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q (MDS-005)	Ongoing	phase 3	Portugal;Spain;Turkey;Austria;Israel;Italy;United Kingdom;France;Czech Republic;Belgium;Poland;Austria	2009-10-05
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma	Active, not recruiting	Phase 1/Phase 2	Switzerland	2009-09-30
Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)	Active, not recruiting	Phase 1/Phase 2	Greece	2009-09-19
Feasibility and efficacy of Lenalidomide maintenance after salvage immuno-chemotherapy induction in relapsed or refractory mantle cell lymphoma - a phase II study of the European MCL Network	Prematurely Ended	phase 2	Germany	2009-09-17
The evaluation of lenalidomide, with or without Docetaxel plus Prednisone, in the treatment of prostate cancer, when the cancer does not respond to hormonal treatment	Ongoing	phase 3	United States;Greece;Spain;Austria;Israel;Russian Federation;Italy;United Kingdom;Hungary;Czech Republic	2009-09-17
Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome	Terminated	Phase 2	Germany	2009-09-14
A phase II study evaluating the efficacy and safety of Lenalidomide (Revlimid®) with or without Epoetin beta (NeoRecormon®) in transfusion-dependent ESA-resistant patients with IPSS low- and intermediate-1 risk myelodysplastic syndromes without chromosome	Ongoing	phase 2	France	2009-09-11
A phase II, multi-center, open-label, repeat-dose study of Lenalidomide (Revlimid®) plus low-dose Dexamethasone in patients with refractory B-cell lineage acute lymphoblastic leukemia or in relapse after two lines of treatment (RV-405 LAL) - RV-405 LA	Ongoing	phase 2	France	2009-09-10
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma	Terminated	Phase 1/Phase 2	United States	2009-09-09
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL	Completed	Phase 2	United States	2009-09-09
Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients	Active, not recruiting	Phase 1	Germany;Germany	2009-09-08
The Treatment of Lenalidomide in Patients With POEMS Syndrome	Recruiting	Phase 2	Italy	2009-09-03



注册题目	招募状态	试验分期	国家	登记时间
Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	Terminated	Phase 2	Italy	2009-08-28
Lenalidomide, Thalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma	Active, not recruiting	Phase 1/Phase 2	United States	2009-08-26
A PHASE 2, OPEN-LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN COMBINATION WITH CETUXIMAB IN PRETREATED SUBJECTS WITH KRAS MUTANT METASTATIC COLORECTAL CANCER		Phase 2	Germany;Belgium;France;Spain;Italy;Sweden	2009-08-25
Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.	Active, not recruiting	Phase 1/Phase 2	Denmark;Finland;Norway;Sweden;Denmark;Finland;Norway;Sweden	2009-08-20
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	Active, not recruiting	Phase 2	United States;Canada;France;Germany;Italy;Spain;Sweden;United Kingdom;Canada;France;Germany;Italy;Spain	2009-08-20
A study for the treatment of patients with leukemic cells in their bone marrow.	Ongoing	phase 2	Belgium;Norway;Netherlands;Switzerland	2009-08-18
RMPT for Relapsed/Refractory Multiple Myeloma	Completed	Phase 2	Italy	2009-08-14
Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients	Completed	Phase 2	Canada	2009-08-11
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	Ongoing	phase 2	France;United States;Canada;Spain;Germany;Italy;United Kingdom;Sweden	2009-07-31
Phase I/II Trial of Lenalidomide in Combination with Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients with Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)	Prematurely Ended	phase 1/phase 2	Austria	2009-07-27
Phase I/II study of lenalidomide and gemcitabine as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. - LENAGEM-PANC	Completed	phase 1/phase 2	Sweden	2009-07-24
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer	Active, not recruiting	Phase 2	United States	2009-07-18
Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer	Completed	Phase 1/Phase 2	United States	2009-07-14
Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients	Terminated	Phase 2	Italy	2009-07-07

注册题目	招募状态	试验分期	国家	登记时间
A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma	Active, not recruiting	Phase 1	United States	2009-07-07
Lenalidomide and Paclitaxel in Prostate Cancer	Terminated	Phase 1/Phase 2	United States	2009-07-03
A phase II study of the efficacy and safety of lenalidomide combined to azacitidine in intermediate-2 or high risk MDS AND AML with del 5q - GFM-Aza-Rev-09	Ongoing	phase 2	France	2009-07-02
A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF CYCLOPHOSPHAMIDE, LENALIDOMIDE AND DEXAMETHASONE (CRD) versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS	Ongoing	phase 3	Hungary;Italy	2009-07-01
A randomised comparison of thalidomide and lenalidomide combinations in myeloma patients of all ages	Recruiting		United Kingdom	2009-06-29
Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes	Terminated	Phase 1	Germany	2009-06-17
Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type	Recruiting	Phase 2	Austria	2009-06-17
Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma	Completed	Phase 2	Germany	2009-06-16
A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Subjects With Previously Treated Multiple Myeloma	Completed	Phase 3	Japan	2009-06-09
A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma	Completed	Phase 1/Phase 2	United Kingdom	2009-06-05
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes	Completed	Phase 1/Phase 2	United States	2009-05-28
Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone	Completed		Germany	2009-05-28
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma	Active, not recruiting	Phase 2	Italy	2009-05-21

注册题目	招募状态	试验分期	国家	登记时间
Lenalidomide and Doxorubicin Hydrochloride Liposome in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Suspended	Phase 1/Phase 2	United States	2009-05-15
Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure	Active, not recruiting	Phase 2	Austria;Czech Republic;Austria;Czech Republic;Slovakia	2009-05-14
Lenalidomide and R-CHOP in B-cell Lymphoma	Active, not recruiting	Phase 1/Phase 2	France	2009-05-13
An open, randomized clinical phase I/II trial to investigate maximum tolerated dose, efficacy, and safety of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide compared to lenalidomide/low-dose dexamethasone combined	Temporarily Halted	phase 1/phase 2	Germany	2009-05-11
Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide	Not yet recruiting			2009-05-09
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)	Active, not recruiting	Phase 2	United States	2009-05-08
A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis	Completed		United States	2009-04-28
Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)	Completed	Phase 1/Phase 2	United States	2009-04-28
PHASE II TRIAL OF LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT)	Completed	phase 2	Austria	2009-04-24
Lenalidomide, bendamustine and rituximab as first-line therapy for patients >65 years with mantle cell lymphoma - LENA-BERIT	Ongoing	phase 1/phase 2	Finland;Denmark;Sweden	2009-04-24
Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma	Active, not recruiting	Phase 3	Germany	2009-04-24
		phase 2	Italy	2009-04-23
A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q	Active, not recruiting	Phase 2	France;France	2009-04-21
A Phase II Study of Low dose ARA-C + Lenalidomide for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) without Deletion 5q in Patients Age 70 Years or Older Who Decline Remission Induction Chemotherapy - ND	Ongoing	phase 2	Italy	2009-04-20

注册题目	招募状态	试验分期	国家	登记时间
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma	Completed	Phase 1	United States	2009-04-16
The combination of Lenalidomide and Dexamethasone with or without intensification by high-dose Melphalan in the treatment of multiple myeloma	Ongoing	phase 3	Germany	2009-04-15
A PHASE 3, INTERGROUP MULTICENTRE, RANDOMIZED, CONTROLLED 3 ARM PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE (Rd) VERSUS MELPHALAN, PREDNISONE AND LENALIDOMIDE (MPR) versus CYCLOPHOSPHAMIDE, P	Ongoing	phase 3	Czech Republic;Italy	2009-04-01
A phase I-II trial of lenalidomide, bendamustin and dexamethasone in the treatment of patients with systemic AL-amyloidosis and ineligible for stem cell transplantation - LeBenD	Ongoing	phase 2	Austria	2009-03-30
A prospective phase I/II, one-arm, one-stage multi-center, open label study of lenalidomide in combination with pioglitazone, dexamethasone and metronomic low-dose chemotherapy with treosulfan in patients with relapsed or refractory or progressive multipl	Ongoing	phase 1/phase 2	Germany	2009-03-30
Trial of High Dose Lenalidomide in Patients With Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Trilineage Dysplasia (AML-TLD)	Active, not recruiting	Phase 2	United States	2009-03-19
Treatment with Lenalidomide, Bendamustine and Prednisone (RBP) in Patients with Relapsed or Refractory Multiple Myeloma after Autologous Stem Cell Transplantation or Conventional Chemotherapy OSHO #077 - OSHO #077	Ongoing	phase 1/phase 2	Germany	2009-03-19
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)	Completed	Phase 1	United States	2009-03-17
A multicenter phase I/II dose escalation study of lenalidomide in relapse/refractory Waldenström macroglobulinemia	Ongoing	phase 1/phase 2	France	2009-03-13
ESSAI EN DEUX ETAPES DE L' EVALUATION DE LA LENALIDOMIDE (REVLIMID®) DANS LE CANCER DE L' OVAIRE EN RECHUTE TARDIVE (> 6 MOIS): - EN MONOTHERAPIE CHEZ DES PATIENTES ASYMPTOMATIQUES AVEC UNE ELEVATION DU TAUX DE CA125 (PHASE II) ; - PUIS EN ASSOCIATION A	Ongoing	phase 2	France	2009-03-12
Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)	Completed	Phase 2	United States	2009-03-10

注册题目	招募状态	试验分期	国家	登记时间
STUDY OF LENALIDOMIDE IN MAINTENANCE VERSUS PLACEBO IN RESPONDING ELDERLY PATIENTS WITH B CELL LYMPHOMA AND PREVIOUSLY TREATED WITH R-CHOP	Ongoing	phase 3	Portugal;France;Poland;Spain;Belgium;Austria;Australia;Israel;Switzerland	2009-02-25
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma	Active, not recruiting	Phase 2	United States	2009-02-19
Lenalidomide (Revlimid®), Adriamycin and Dexamethasone (RAD) as an Induction Therapy in Newly Diagnosed Multiple Myeloma Followed by a Risk-Defined Transplant Strategy and Lenalidomide Maintenance – A Multicenter Phase II Trial by Deutsche Studiengruppe M	Ongoing	phase 2	Germany	2009-02-17
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma	Completed	Phase 2	United States	2009-02-17
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma	Terminated	Phase 2	United States	2009-02-12
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia	Active, not recruiting	Phase 3	United States	2009-02-12
Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas	Completed	Phase 2	United States	2009-02-04
Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)	Active, not recruiting	Phase 1	United States	2009-02-04
Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant	Withdrawn	Phase 2	United States	2009-01-30
Lenalidomide maintenance following tandem autologous stem cell and non myeloablative allogeneic transplantation for patients with multiple myeloma <= 66 years.	Recruiting		The Netherlands	2009-01-29
Phase 1/2 Study of Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)	Active, not recruiting	Phase 1/Phase 2	United States	2009-01-28
A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia	Recruiting	Phase 1/Phase 2	United States	2009-01-23
PHASE II STUDY OF LENALIDOMIDE IN COMBINATION WITH RITUXIMAB (R) FOR THE TREATMENT OF INDOLENT NON FOLLICULAR NON HODGKIN LYMPHOMA - ND	Ongoing	phase 2	Italy	2009-01-22
Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes	Completed	Phase 1	United States	2009-01-22

注册题目	招募状态	试验分期	国家	登记时间
Study of the Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes	Completed	Phase 2	United States	2009-01-21
Lenalidomide In Patients With Acute Myeloid Leukemia	Terminated	Phase 1	Germany	2009-01-20
A Phase II randomized multicenter study to assess the efficacy of lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor in patients with low and intermediate-1 risk myelodysplastic syndrome - HOVON 89 MDS	Ongoing	phase 2	Netherlands	2008-12-31
Study of Lenalidomide to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndromes (MDS) With a Del(5)(q31-33) Abnormality.	Completed	Phase 2	Japan	2008-12-17
Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L	Active, not recruiting	Phase 2	United States	2008-12-11
evaluation of the efficacy of lenalidomide versus investigator choice treatment in patients with mantle cell lymphoma, whose disease has returned after it completely or almost completely disappeared or whose disease did not respond to prior treatment.	Ongoing	phase 2	France;Czech Republic;Spain;Belgium;Denmark;Russian Federation;Israel;Germany;Italy;United Kingdom;S	2008-11-20
Pharmacogenomic study to predict survival, best response and toxicity in newly diagnosed myeloma patients who are either 65 years of age or older treated with either a combination of melphalan-prednisone-thalidomide or lenalidomide-dexamethasone	Ongoing	phase 3	Belgium	2008-11-18
A phase ii study of the efficacy and safety of lenalidomide combined to escalating doses of chemotherapy in intermediate-2-or high risk MDS and AML with del 5 q31 - GFM-chimio-Rev-08	Completed	phase 2	France	2008-11-14
A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue	Active, not recruiting		United States	2008-11-13
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction	Active, not recruiting	Phase 1/Phase 2	United States	2008-11-13
Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant - MM-ALLO-06-07_BIS	Ongoing	phase 2	Italy	2008-11-11



注册题目	招募状态	试验分期	国家	登记时间
Salvage Treatment With Lenalidomide and Dexamethasone (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)	Active, not recruiting	Phase 2	Italy	2008-11-05
Lenalidomide and Dexamethasone for treatment of patients with acute myeloma (light chain)-induced renal failure	Completed	phase 2	Czech Republic;Austria;Germany	2008-11-04
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma	Completed	Phase 2	United States	2008-11-01
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL)	Ongoing	phase 3	Portugal;United States;Spain;Ireland;Austria;Russian Federation;Israel;Italy;United Kingdom;France;C	2008-10-31
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas	Active, not recruiting	Phase 2	United States	2008-10-30
Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function	Recruiting	Phase 2	France	2008-10-23
Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma	Completed	Phase 1/Phase 2	Germany	2008-10-22
Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple Myeloma	Active, not recruiting	Phase 4	United States	2008-10-21
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy	Active, not recruiting	Phase 3	United States;Australia;Austria;Belgium;Canada;Colombia;Czech Republic;Denmark;France;Germany;Hungary	2008-10-16
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma	Active, not recruiting	Phase 2	United States	2008-10-12
Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma	Completed	Phase 2	United States	2008-10-01
Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia	Completed	Phase 2	United States	2008-09-24
Randomized phase III trial in elderly patients with previously untreated symptomatic Multiple Myeloma comparing MP-Thalidomide (MP-Thal) followed by thalidomide maintenance versus MP-Lenalidomide (MP-Len) followed by maintenance with lenalidomide	Ongoing	phase 3	Netherlands;Denmark;Belgium;Norway;Sweden	2008-09-15



注册题目	招募状态	试验分期	国家	登记时间
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)	Terminated	Phase 2	Canada	2008-09-10
Dose-finding study of lenalidomide as maintenance therapy in multiple myeloma after allogeneic stem cell transplantation - Revlimid as Maintenance in MM	Completed	phase 1/phase 2	Germany	2008-09-04
Phase II Single Agent Lenalidomide (Revlimid) in Relapsed / Refractory Mantle Cell Lymphoma. - Lenalidomide Study	Ongoing	phase 2	United Kingdom	2008-09-02
A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX) - LEOMEX	Completed	phase 2	Germany	2008-08-28
A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma	Active, not recruiting	Phase 2	United States;Canada;France;Germany;Canada;France;Germany;United States	2008-08-25
A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial	Active, not recruiting	Phase 2	United States;Austria;Belgium;Colombia;France;Germany;Hungary;Israel;Italy;Puerto Rico;Singapore;Spain	2008-08-15
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Completed	Phase 1	United States	2008-08-14
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma	Active, not recruiting	Phase 1	United States	2008-08-06
RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma	Completed	Phase 1	United States	2008-08-04
Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy	Active, not recruiting	Phase 1/Phase 2	Italy	2008-08-01
A randomised comparison of daily 25 mg versus 5 mg lenalidomide as maintenance therapy after high-dose therapy and autologous stem cell transplantation in patients with multiple myeloma.	Ongoing	phase 3	Germany	2008-07-29
PHARMACOKINETICS, SAFETY AND EFFICACY OF LENALIDOMIDE (REVLIMID®) IN COMBINATION WITH DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND IMPAIRED RENAL FUNCTION	Ongoing	phase 1/phase 2	France	2008-07-28

注册题目	招募状态	试验分期	国家	登记时间
Fludarabine/Rituximab combined with escalating doses of Lenalidomide followed by Rituximab/Lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with concomitant evaluation of safety and efficacy - RevliRit	Completed	phase 1/phase 2	Austria	2008-07-23
Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)	Terminated	Phase 2	Germany	2008-07-17
Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial	Completed	Phase 2	United States	2008-07-15
Pilot safety/tolerability study of Lenalidomide administered as monotherapy and in combination with standard chemotherapy for Acute Myeloid Leukaemia/high-risk myelodysplastic syndrome with structural abnormalities of chromosome 5			United Kingdom	2008-07-11
NA	Ongoing	phase 2	Italy	2008-07-11
Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas	Terminated	Phase 0	United States	2008-06-21
Lenalidomide for Myelodysplastic Syndromes: Efficacy, Safety, Cardiac Changes, and Quality of Life (QoL-ESC RevMDS) - QoL-ESC RevMDS	Completed	phase 2	Italy	2008-06-16
A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients	Terminated	Phase 1/Phase 2	United States	2008-06-13
A phase II trial to evaluate the safety and activity of single-agent lenalidomide given as maintenance therapy after response to second-line therapy in patients with relapsed diffuse large B cell lymphoma, not eligible for high-dose chemotherapy and autol	Ongoing	phase 2	Italy	2008-06-13
Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma	Recruiting	Phase 1/Phase 2	United States	2008-06-12
Lenalidomide Plus Rituximab for Indolent Non-Hodgkin's Lymphoma	Active, not recruiting	Phase 2	United States	2008-06-10
Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy	Completed	Phase 2	United States	2008-06-03
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma	Terminated	Phase 1/Phase 2	United States	2008-05-30
Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain	Terminated	Phase 2	United States	2008-05-22

注册题目	招募状态	试验分期	国家	登记时间
Phase II study of the combination of Lenalidomide and Alemtuzumab as consolidation in patients who responded to a previous chemotherapeutic regimen administered for relapsed or refractory Chronic Lymphocytic Leukemia (CLL) - len-cam	Prematurely Ended	phase 2	Italy	2008-05-20
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis	Completed	Phase 2	United States	2008-05-14
Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)	Terminated	Phase 2	United States	2008-05-07
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I	Terminated	Phase 1	United States	2008-04-30
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma	Recruiting	Phase 1/Phase 2	United States	2008-04-30
Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance	Suspended	Phase 2	United States	2008-04-22
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma	Active, not recruiting	Phase 1/Phase 2	United States;Canada;United States;Canada	2008-04-11
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	Completed	Phase 2	United States	2008-04-02
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma	Active, not recruiting	Phase 3	United States;Puerto Rico;Saudi Arabia;United States;Saudi Arabia;Puerto Rico	2008-03-22
Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)	Completed	Phase 1	France;Greece;United States	2008-03-17
Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in elderly patients in 1st relapse or primary refractory after first line therapy for Multiple Myeloma - HOVON 86 MM		phase 1/phase 2	Netherlands;Belgium	2008-03-13
Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)	Completed		United States	2008-03-04
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma	Active, not recruiting	Phase 1/Phase 2	United States	2008-03-04
Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease	Completed	Phase 2	United States	2008-03-03

注册题目	招募状态	试验分期	国家	登记时间
Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant	Completed	Phase 2	United States	2008-02-20
A PHASE III, RANDOMIZED, OPEN-LABEL, 3-ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) PLUS LOW-DOSE DEXAMETHASONE WHEN GIVEN UNTIL PROGRESSIVE DISEASE OR FOR 18 FOUR-WEEK CYCLES VERSUS THE COMBINATION OF MELPHALAN, PREDNISONE, A	Ongoing	phase 3	Portugal;Germany;United Kingdom;Belgium;France;Spain;Ireland;Italy;Greece;Austria;Sweden	2008-02-14
Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis	Completed	Phase 1/Phase 2	France	2008-02-12
Lenalidomide in Combination With Rituximab for Patients With CD5+/CD20+ Hematologic Malignancies Who Relapse/Progress After Rituximab	Completed	Phase 2	United States	2008-01-24
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia	Active, not recruiting	Phase 2	United States;Canada;United States;Canada;United States;Canada;United States;Canada	2008-01-23
Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis	Completed	Phase 2	Italy	2008-01-22
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma	Active, not recruiting	Phase 3	United States;Israel;United States;Israel	2008-01-18
Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma	Completed	Phase 1	United States;Canada;United States;Canada	2008-01-16
Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Active, not recruiting	Phase 2	United States	2008-01-12
Phase I (II) study of the combination of lenalidomide and alemtuzumab in patients with chemotherapy refractory chronic lymphocytic leukemia (CLL)	Completed	phase 1/phase 2	Sweden	2007-12-28
A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia	Completed	Phase 1	United States	2007-12-20
An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previously treated patients with AL amyloidosis - ND	Prematurely Ended	phase 2	Italy	2007-12-10
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma	Terminated	Phase 2	United States	2007-12-01

注册题目	招募状态	试验分期	国家	登记时间
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis	Completed	Phase 2	United States	2007-11-28
Dasatinib in Combination With Revlimid (and Dexamethasone)	Completed	Phase 1	United States;Australia;France;United States;Australia;France;Netherlands	2007-11-16
Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma	Completed	Phase 1	Japan	2007-11-06
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma	Active, not recruiting	Phase 2	United States	2007-11-02
Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients	Active, not recruiting	Phase 3	Italy;Israel	2007-10-30
Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities	Completed	Phase 2	United States	2007-10-17
Lenalidomide maintenance therapy in patients with MDS or AML with cytogenetic abnormalities involving monosomy 5 or del5q after allogeneic hematopoietic stem cell transplantation (HSCT) - LENAMAINT TRIAL	Prematurely Ended	phase 2	Germany	2007-10-15
Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL	Terminated	Phase 1	United States	2007-10-10
Prospective multicenter phase I-II pilot trial to evaluate efficacy and safety of treatment with Lenalidomide plus R-CHOP21 (LR-CHOP21) for elderly patients with untreated Diffuse Large B-Cell Lymphoma (DLBCL). - REAL07	Completed	phase 2	Germany;Italy	2007-10-05
Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma	Active, not recruiting	Phase 2	United States	2007-10-04
Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma	Recruiting	Phase 2	United States	2007-10-02
Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma	Active, not recruiting	Phase 2	United States	2007-10-02
A PHASE II, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE-AGENT LENALIDOMIDE (REVLIMID®) IN SUBJECTS WITH RELAPSED OR REFRACTORY T-CELL NON-HODGKIN' S LYMPHOMA - TCL-001		Phase 2	Belgium;France	2007-10-01
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older	Completed	Phase 2	United States	2007-09-25

注册题目	招募状态	试验分期	国家	登记时间
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)	Active, not recruiting	Phase 1/Phase 2	United States	2007-09-24
Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.	Active, not recruiting	Phase 1	United States;Australia;France;Spain;Australia;France;Spain;United States;Italy	2007-09-18
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma	Completed	Phase 1	United States	2007-08-31
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone	Terminated	Phase 3	United States;South Africa;United States;South Africa	2007-08-28
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients	Completed	Phase 1/Phase 2	United States	2007-07-25
A Phase I/II trial of lenalidomide combined with cyclophosphamide and intermediate dose dexamethasone in patients with primary (AL) systemic amyloidosis - CDR in amyloidosis	Completed	phase 1/phase 2	Greece	2007-07-18
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)	Completed	Phase 1	United States	2007-07-13
A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS - MPR vs M	Ongoing	phase 3	Italy	2007-06-12
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma	Terminated	Phase 2	United States	2007-06-04
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression	Active, not recruiting	Phase 2	Australia	2007-06-03
A multicentre phase II study of the efficacy and safety of lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q) or monosomy 5. - Lenalidomide in high-risk myeloid disease with 5q-	Completed	phase 2	Denmark;Sweden	2007-06-01
Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma	Completed	Phase 2	Canada	2007-05-24
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma	Active, not recruiting	Phase 1/Phase 2	United States	2007-05-23



注册题目	招募状态	试验分期	国家	登记时间
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma	Completed	Phase 2	United States	2007-05-23
A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Terminated	Phase 2	United States;Australia;Canada;United States;Australia;Canada	2007-05-14
Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.	Active, not recruiting	Phase 1	United States	2007-04-26
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome	Active, not recruiting	Phase 2	United States	2007-04-25
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy	Active, not recruiting	Phase 2	United States	2007-04-11
A phase II study of the efficacy and the safety of lenalidomide in subjects with intermediate or the high risk myelodysplastic syndromes (MSD) associated with a deletion (Del) 5q[31]	Ongoing	phase 2	Belgium	2007-03-21
A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF LENALIDOMIDE, MELPHALAN, PREDNISONE AND THALIDOMIDE R-MPT IN ADVANCED, RELAPSED, REFRACTORY MULTIPLE MYELOMA PATIENTS. - R.MPT	Ongoing	phase 2	Italy	2007-03-09
Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma	Completed	Phase 2	United States	2007-03-07
Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma	Active, not recruiting	Phase 2	United States	2007-03-07
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Completed	Phase 2	United States	2007-02-22
Lenalidomide and Recombinant Human Stem Cell Factor for Treatment of Myelodysplasia	Active, not recruiting	Phase 0	Australia	2007-02-11
Lenalidomide maintenance following tandem autologous stem cell and non myeloablative allogeneic transplantation for patients with multiple myeloma <= 66 years who have been treated in or according to the HOVON 65/GMMG-HD4 study. - HOVON 76 MM	Prematurely Ended	phase 2	Netherlands	2007-02-07
Maintenance Therapy Using Lenalidomide in Myeloma	Active, not recruiting	Phase 3	Belgium;France;Switzerland;Belgium;France;Switzerland	2007-01-31
A Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Patients With Multiple Myeloma	Completed	Phase 3	Australia;Austria;Belgium;France;Germany;Greece;Ireland;Israel;Italy;Poland;Spain;Sweden;Switzerland	2007-01-17



注册题目	招募状态	试验分期	国家	登记时间
Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]	Recruiting	Phase 2	France	2007-01-15
A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia	Completed	Phase 1	United States;Canada;Germany;Italy;Spain;Sweden;United Kingdom;United States;Canada;Germany;Italy;Sp	2007-01-05
A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid	Completed	Phase 2	United States	2007-01-04
Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors	Completed	Phase 1		2006-12-21
Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma	Completed	Phase 1	United States	2006-12-20
A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma	Completed	Phase 2	United States;Canada;France;Germany;Italy;Spain;United Kingdom;United States;Canada;France;Germany;I	2006-12-18
Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma	Completed	Phase 1	United States	2006-12-14
Bevacizumab, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Stage II or Stage III Multiple Myeloma	Active, not recruiting	Phase 2	United States	2006-12-11
A PHASE II, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE-AGENT LENALIDOMIDE (REVLIMID®) IN SUBJECTS WITH RELAPSED OR REFRACTORY AGGRESSIVE NON-HODGKIN' S LYMPHOMA		Phase 2	France;Spain;Germany;United Kingdom;Italy	2006-12-06
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer	Active, not recruiting	Phase 2	United States	2006-11-21
A MULTICENTER, SINGLE-ARM, OPEN-LABEL EXPANDED ACCESS PROGRAM FOR LENALIDOMIDE PLUS DEXAMETHASONE IN PREVIOUSLY TREATED SUBJECTS WITH MULTIPLE MYELOMA - CC-5013-MM-019			Germany	2006-11-16
Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma	Completed	Phase 1	United States	2006-11-09

注册题目	招募状态	试验分期	国家	登记时间
A PHASE 1/2, MULTI-CENTER, OPEN LABEL STUDY OF THE SAFETY AND EFFICACY OF A STEPWISE DOSE-ESCALATION SCHEDULE OF LENALIDOMIDE MONOTHERAPY IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA		Phase 1/Phase 2	United Kingdom; France; Italy; Sweden	2006-11-08
A clinical study to compare the effectiveness and safety of the combination of lenalidomide, melphalan and prednisone with placebo, melphalan and prednisone in newly diagnosed Multiple Myeloma patients who are 65 years or older.	Completed	phase 3	Belarus; Greece; Spain; Ukraine; Ireland; Turkey; Austria; Russian Federation; Israel; United Kingdom; Switzerland	2006-11-02
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma	Active, not recruiting	Phase 1/Phase 2	United States	2006-09-18
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma	Active, not recruiting	Phase 2	United States	2006-09-18
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome	Completed	Phase 2	United States	2006-08-04
Lenalidomide for Patients With Myelofibrosis (MF)	Active, not recruiting	Phase 2	United States	2006-07-14
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia	Completed	Phase 2	United States	2006-07-13
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes	Completed	Phase 1/Phase 2	United States	2006-07-13
A multicenter, single-arm, open-label safety study of lenalidomide plus dexamethasone in previously treated subjects with Multiple Myeloma.			United Kingdom; Spain; Ireland; Austria	2006-07-07
Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer	Active, not recruiting	Phase 1/Phase 2	United States	2006-06-30
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma	Completed	Phase 2	Canada	2006-05-05
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma	Completed	Phase 2	Canada	2006-03-21
Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma	Completed	Phase 1/Phase 2	Germany	2006-03-15
Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma	Completed	Phase 1/Phase 2	United States	2006-02-20
REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas	Active, not recruiting	Phase 2	United States	2006-02-03

注册题目	招募状态	试验分期	国家	登记时间
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)	Completed	Phase 2	United States	2005-12-19
Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors	Completed	Phase 1	United States	2005-11-11
Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab	Active, not recruiting	Phase 2	United States	2005-10-12
Lenalidomide and Prednisone in Treating Patients With Myelofibrosis	Completed	Phase 2	United States;Israel	2005-09-26
Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy	Completed	Phase 1	United States	2005-09-13
Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)	Completed	Phase 2	United States	2005-09-13
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma	Completed	Phase 3	United States;Canada;United States;Canada	2005-09-13
Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis	Completed	Phase 2	United States	2005-09-12
Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma	Completed	Phase 2	United States;Canada;United States;Canada	2005-09-10
A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas	Terminated	Phase 1/Phase 2	United States	2005-09-10
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.	Terminated	Phase 2	United States	2005-09-10
A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer	Completed	Phase 2	United States	2005-09-10
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer	Terminated	Phase 1	United States	2005-09-10
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma	Terminated	Phase 1/Phase 2	United States	2005-09-10
Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma	Completed	Phase 1/Phase 2	United States	2005-09-10

注册题目	招募状态	试验分期	国家	登记时间
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme	Completed	Phase 2	United States	2005-09-09
Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma	Active, not recruiting	Phase 2	United States	2005-09-06
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy	Completed	Phase 2/Phase 3	United States	2005-07-08
Lenalidomide in Treating Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma	Active, not recruiting	Phase 3	United States	2005-06-13
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma	Active, not recruiting	Phase 1/Phase 2	United States	2005-06-02
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1	Terminated	Phase 2	United States	2005-05-03
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma	Completed	Phase 2	United States	2005-04-21
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes	Completed	Phase 1	United States;Canada	2005-03-03
A study to evaluate if Lenalidomide works in patients with myelodysplastic syndrome and with a special genetic characteristic of the disease, and who need to receive blood transfusion	Ongoing		France;Spain;Belgium;Israel;Germany;Italy;United Kingdom;Sweden	2005-02-23
The purpose of the study is to determine if the drug lenalidomide (Revlimid®) is able to improve anaemia (low red blood count) and reduce the number of blood transfusions that you require because of Myelodysplastic Syndrome (MDS). The other purpose of th	Ongoing	phase 2	United Kingdom	2005-02-23
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors	Completed	Phase 1	United States	2005-01-06
Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma	Active, not recruiting	Phase 3	United States	2004-12-07
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer	Completed	Phase 2	United States	2004-11-09
Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	Active, not recruiting	Phase 2	United States	2004-11-09
Pentostatin, Cyclophosphamide, and Rituximab Followed By Lenalidomide in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia	Recruiting	Phase 2	United States	2003-12-10

注册题目	招募状态	试验分期	国家	登记时间
<a href="#">Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality</a>	Completed	Phase 2	United States;Germany;United States;Germany	2003-07-17
<a href="#">S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma</a>	Completed	Phase 3	United States	2003-07-08
<a href="#">Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)</a>	Recruiting	Phase 3		2015-10-16
<a href="#">Lenalidomide &amp; Adriamycin &amp; Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients</a>	Active, not recruiting	Phase 2		2015-06-05
<a href="#">Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma</a>	Recruiting	Phase 3		2014-11-04
<a href="#">Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia</a>	Active, not recruiting	Phase 1/Phase 2		2014-06-24
<a href="#">Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma</a>	Active, not recruiting	Phase 2		2013-09-24
<a href="#">Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)</a>	Recruiting	Phase 3		2013-09-05
<a href="#">PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)</a>	Active, not recruiting	Phase 3		2013-06-28
<a href="#">IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma</a>	Active, not recruiting	Phase 3		2013-04-26
<a href="#">Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas</a>	Recruiting	Phase 1/Phase 2		2013-02-04
<a href="#">Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL</a>	Completed	Phase 1/Phase 2		2012-10-04
<a href="#">Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma</a>	Active, not recruiting	Phase 2		2012-09-27

注册题目	招募状态	试验分期	国家	登记时间
A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma	Active, not recruiting	Phase 3		2012-07-24
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance	Recruiting	Phase 3		2012-06-27
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma	Active, not recruiting	Phase 1/Phase 2		2012-06-06
The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del(5q).	Recruiting	Phase 2		2012-03-12
Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia	Completed	Phase 2		2012-03-03
Use of Thalidomide, Lenalidomide, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients	Recruiting	Phase 3		2012-02-21
Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma	Completed	Phase 2		2011-09-07
Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus	Completed	Phase 4		2011-07-19
STUDY WITH LENALIDOMIDE (Revlimid®) MAINTENANCE VS OBSERVATION AFTER INTENSIFIED INDUCTION REGIMEN CONTAINING RITUXIMAB FOLLOWED BY HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION AS FIRST LINE TREATMENT IN ADULT PATIENTS WITH ADVANCED MAN	Recruiting	Phase 3		2011-06-23
Lenalidomide in Patients With Chronic Myelomonocytic Leukemia	Active, not recruiting	Phase 1/Phase 2		2011-05-09
Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma	Active, not recruiting	Phase 2		2011-03-01
Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant	Recruiting	Phase 2		2010-12-20
Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome	Recruiting	Phase 3		2010-11-17

注册题目	招募状态	试验分期	国家	登记时间
Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma	Active, not recruiting	Phase 3		2010-09-23
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)	Active, not recruiting	Phase 2/Phase 3		2010-07-29
Repeat-dose Study of Lenalidomide (Revlimid 芦) Plus Dexamethasone in Patients With Lymphoblastic Leukemia	Recruiting	Phase 2		2010-04-26
Lenalidomide Maintenance Post-debulking in Advanced CTCL	Terminated	Phase 3		2010-04-02
A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer	Terminated	Phase 2		2009-12-14
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer	Active, not recruiting	Phase 3		2009-10-01
Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)	Terminated	Phase 1/Phase 2		2009-09-07
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)	Active, not recruiting	Phase 3		2009-05-28
Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD	Completed	Phase 2		2009-05-21
Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone	Active, not recruiting			2009-05-20
A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis	Completed	Phase 2		2009-04-15
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)	Active, not recruiting	Phase 2		2009-04-01
The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality	Active, not recruiting	Phase 2		2009-03-16
Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma	Recruiting	Phase 2		2008-11-20



注册题目	招募状态	试验分期	国家	登记时间
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5	Completed	Phase 2		2008-09-26
Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL	Completed	Phase 1/Phase 2		2008-08-20
Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma	Active, not recruiting	Phase 3		2008-06-02
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma	Terminated	Phase 2		2008-04-04
QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression	Completed	Phase 3		2007-05-28
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma	Completed	Phase 3		2007-05-23
A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma	Completed	Phase 3		2007-01-09
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality	Completed	Phase 3		2005-09-10
Clinical research of the efficacy and safety of Vitamin A acid combined with Rd scheme in multiple myeloma patients with the drug lenalidomide resistance,Single center, single arm, prospectie ? studies	Recruiting		China	2016-04-07
Adherence to Lenalidomide Treatment in Multiple Myeloma - Prevalence, Characteristics and Clinical Significance	Not yet recruiting			2016-04-05
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)	Not yet recruiting	Phase 2	United States	2016-03-30
A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)	Not yet recruiting	Phase 2		2016-03-09
Prediction of the lenalidomide toxicity and its therapeutic efficacy in multiple myeloma patients by measuring its plasma concentration	Enrolling by invitation			2016-05-16
The association of Cytokine /chemokine profiles with the clinical outcome and safety in relapsed/refractory multiple myeloma patients treated with lenalidomide plus dexamethasone	Open public recruiting			2016-05-11

注册题目	招募状态	试验分期	国家	登记时间
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement	Not yet recruiting	Phase 2	United States	2016-05-05
An open label, randomized, single-dose, two-period, two-sequence, crossover pivotal study to assess the bioequivalence of Lenalidomide capsules 25mg in healthy adult subjects under fasting/ Fed condition	Recruiting	phase 1	China	2016-06-29
Lenalidomide consolidation post allogeneic stem cell transplant for patients with high risk multiple myeloma failing to achieve stringent Complete Response	Not recruiting	Phase 2	Australia	2016-06-15
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat	Not yet recruiting	Phase 1/Phase 2	United States	2016-06-13
Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients	Not yet recruiting	Phase 2		2016-07-20
Study to determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients who have been newly diagnosed with multiple myeloma and have not received previous anti-myeloma treatment	Ongoing	phase 3	United States;France;Canada;Belgium	2013-04-22
A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma	Not yet recruiting	Phase 1	United States	2016-08-28
A Phase IIb, open label, sequential cohort study comparing KappaMab alone to KappaMab in combination with lenalidomide and low dose dexamethasone (MRd) in Relapsed Refractory Multiple Myeloma	Not recruiting	Phase 2	Australia	2016-08-26
Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant	Not yet recruiting	Phase 2	United States	2016-08-18
Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma	Not yet recruiting	Phase 2	United States	2016-08-15
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy	Not yet recruiting	Phase 2	Austria	2016-08-10
Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma	Recruiting	Phase 1/Phase 2	United States	2016-08-08

注册题目	招募状态	试验分期	国家	登记时间
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma	Recruiting	Phase 2	United States	2016-08-01
Phase II Trial of Plitidepsin (Aplidin®) in Combination with Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to bortezomib and lenalidomide .	Authorised	phase 2	Spain	2016-08-01
A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation	Recruiting	phase 1	Japan	2016/9/30
A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation	Not yet recruiting	Phase 1	Japan;Japan	2016/9/27
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma	Not yet recruiting	Phase 2	United States;United States	2016/9/26
Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome	Not yet recruiting		United States;United States	2016/9/26
A Phase 2, Open-Label, Multicenter Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Patients With Relapsed and/or Refractory Multiple Myeloma	Not yet recruiting	Phase 2	Japan;Japan	2016/9/22
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma	Not yet recruiting	Phase 1/Phase 2	United States;United States	2016/9/21
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma	Not yet recruiting	Phase 1/Phase 2	United States	2016/9/8
Early Patient Access Treatment Use Protocol CA204-220	Available		Japan;Japan	2016/8/2
Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan	Active, not recruiting	Phase 2	Japan	2014/10/21
A Phase 2, Open-Label, Multicenter Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Patients With Relapsed and/or Refractory Multiple Myeloma	Not Recruiting	2	Japan	2016-10-25
High Dose Carfilzomib for Newly Diagnosed Myeloma	Recruiting	Phase 1/Phase 2	United States	2016-10-17

注册题目	招募状态	试验分期	国家	登记时间
Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q	Recruiting	Phase 2	France;Italy;France;Italy;France;Italy;France;Italy	2016-10-05
MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma	Not recruiting	Phase 1	United States	2017-01-25
Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma	Not recruiting	Phase 2	Austria;Italy;Spain;Austria;Italy;Spain	2017-01-23
MUK eleven: Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma	Recruiting	phase 1	United Kingdom	2017-01-11
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma	Not recruiting	Phase 2	United States	2017-01-05
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant	Not recruiting	Phase 1/Phase 2	United States	2017-01-04
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma	Not recruiting	Phase 1/Phase 2	United States	2017-01-04
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma	Not recruiting	Phase 1/Phase 2	United States	2017-01-03
Multicenter study to compare the combination of Melflufen/ Dexamethasone vs.Pomalidomide/Dexamethasone in patients with Relapsed Refractory Multiple Myeloma.	Authorised		United States;Greece;Spain;Israel;United Kingdom;Italy;France;Hungary;Czech Republic;Belgium;Poland;Denmark;Netherlands	2016-12-21
Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients	Not recruiting		Austria	2016-12-19
Lintuzumab-Ac225 for Refractory Multiple Myeloma	Recruiting	Phase 1	United States	2016-12-12
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	Not recruiting	Phase 1	United States	2016-12-12
Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma	Recruiting	Phase 2	China	2016-12-06
Efficacy of eltrombopag plus lenalidomide combination therapy in patients with IPSS low and intermediate-risk myelodysplastic syndrome with isolated del5q: a multicenter, randomized, double-blind, placebo controlled study	Authorised	phase 2	France	2016-11-30

注册题目	招募状态	试验分期	国家	登记时间
Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma	Not recruiting	Phase 1	United Kingdom	2016-11-16
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma	Not recruiting	Phase 2	United States	2016-11-14
Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone in Patients With Multiple Myeloma	Recruiting		Germany	2016-11-10
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer	Not recruiting	Phase 1/Phase 2	United States	2016-11-09
Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvement of Cardiac Amyloidosis	Recruiting	Phase 2	Korea, Republic of	2016-11-08
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma	Not recruiting	Phase 1	United States;Canada;United States	2016-11-02
A Combination of Lenalidomide and Rituximab as Front Line Therapy for the Treatment of Elderly Frail Patients Evaluated in CGA With Diffuse Large B-cells Non-Hodgkin Lymphoma. A Phase II Study of the Fondazione Italiana Linfomi (FIL)	Not recruiting	Phase 2	Italy	2016-11-02
Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide	Recruiting		United States	2017-02-23
Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma	Not recruiting	Phase 2	Singapore	2017-02-13
Selinexor Treatment of Refractory Myeloma	Recruiting	Phase 2	United States;United States	2015-01-08
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma	Not recruiting	Phase 3	United States;Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Turkey;United Kingdom;Austria	2012-03-22